The antimicrobial effect of hydrastis canadensis mother tincture and herbal extract on staphylococcus aureus and escherichia coli in-vitro by Daniels, Chesné
I 
The Antimicrobial Effect of Hydrastis canadensis Mother 
Tincture and Herbal Extract on Staphylococcus aureus and 
Escherichia coli in-vitro 
A dissertation submitted to the 
Faculty of Health Science, University of Johannesburg, 
As partial fulfilment for 
 The Master’s degree in Technology: Homoeopathy  
By 
Chesné Daniels 
(Student Number: 201145718) 
Supervisor:        Date: 
Dr. T. Tsele-Tebakang M.Tech Hom (UJ) 
Co-supervisor:     Date: 
Prof. TG. Barnard PhD (Biochemistry) (UJ) 
             Johannesburg, 2019
III 
DECLARATION 
IV 
ABSTRACT 
Antibiotic resistance has become one of the largest threats to the health of 
human beings worldwide. The combination of large amounts of antibiotics 
prescribed over many decades has resulted in the rapid development of 
bacterial resistance. The spread of multiple antibiotic resistant organisms 
are becoming more prevalent, traditional antibiotics are no longer effective 
and the rate at which new antibiotics are developed has significantly 
dropped in the last decades. There is an urgent need for new therapeutic 
approaches for the treatment of illnesses caused by bacteria. 
The aim of this study was to determine the antimicrobial effect of Hydrastis 
canadensis herbal extract and Hydrastis canadensis mother tincture on 
Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) reference 
strains. These organisms where chosen since infections caused by them 
are commonly treated with a wide variety of antibiotics that produces 
undesirable side effects. S. aureus and E. coli have developed resistance 
to many classes of antibiotics which makes formerly treatable conditions 
increasingly difficult to treat. 
This study was done by means of the Kirby-Bauer Disk Diffusion Method 
and Microdilution method to determine the Minimum Inhibitory 
Concentration (MIC) of the Hydrastis canadensis herbal extract and 
Hydrastis canadensis mother tincture. Cultures on agar plates (for use with 
the Kirby-Bauer Disk Diffusion test) or in liquid cultures (for use with broth 
dilution cultures) were grown overnight at 35°C for 16-18 hours. Sterile 
disks were impregnated with the Hydrastis canadensis herbal extract and 
Hydrastis canadensis mother tincture. Following incubation the plates 
were examined for a zone of inhibition of bacterial growth and the zone 
measured in millimetres. To determine the Minimum Inhibitory 
Concentration (MIC) of the compounds, the serial dilution method in 96 
well plates were tested, labeled and into each well 100 µl Mueller-Hinton 
broth was added. The compound to be tested (50 µl) was added to the first 
V 
well, mixed and 50 µl removed, added to the next well and repeated for 
the next four wells. The 50 µl removed from the sixth well and discarded. 
After the incubation period 50 µl Iodonitrotetrazolium chloride (INT) dye 
was added to the wells, incubated at 35°C for up to 30 min, to produce a 
pink to dark purple color. 
The results demonstrated that Hydrastis canadensis herbal extract and 
Hydrastis canadensis mother tincture inhibited the growth of S. aureus 
which was confirmed by the Kirby-Bauer Disk Diffusion and Microdilution 
methods. The Hydrastis canadensis herbal extract and Hydrastis 
canadensis mother tincture inhibited the growth of E. coli but was only 
confirmed by the adaptation of the 96 well microdilution methods by 
increasing the concentration of the Hydrastis canadensis herbal extract 
and Hydrastis canadensis mother tincture as well as forcing the E. coli into 
contact with the substances. The Hydrastis canadensis herbal extract and 
Hydrastis canadensis mother tincture showed no antimicrobial effects 
when tested with the Kirby-Bauer Disk Diffusion method as bacterial 
swarming, minimum dosing or decreased concentration of the active 
compounds could have been a factor. Further investigation into why the 
Microdilution method yielded positive results rather than the Kirby-Bauer 
Disk Diffusion method for E. coli found that E. coli’s flagella driven motility 
allowed the bacteria to swim away and protect itself from the compound 
resulting in a false negative. When E. coli was forced into contact with the 
compound, inhibition of growth was observed. Overall it was found that the 
herbal extract had a greater antimicrobial effect than the mother tincture. 
In conclusion, Hydrastis canadensis did work against S. aureus and to an 
extent against E. coli when forced into contact with the Hydrastis 
canadensis but we need a better understanding of whether it is 
bactericidal or bacteriostatic. It needs to be ensured that when using this, 
it is the correct method and that we test and expand the number of strains 
to determine if there is no interchange and how it relates to antibiotic 
resistance. 
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CHAPTER ONE 
1.  INTRODUCTION 
1.1 Problem statement  
The prevalence of disease has increased dramatically in recent years. The 
discovery of antibiotics has revolutionised western medicine, however the 
overwhelming influx of patients requiring health care has exceeded the 
development of new antibiotics or therapeutic approaches (Richardson, 
2017). The combination of large amounts of antibiotics prescribed over 
decades has resulted in the emerging and increasing risk of bacterial 
resistance to these antibiotics (Ventola, 2015). The development of the 
resistance to antibiotics has become one of the largest threats to the 
health of human beings worldwide (World Health Organization, 2017).  
Bacterial resistance to antimicrobial drugs can occur due to genetic 
mutation of the bacteria, acquiring resistance from other bacteria and 
adaptation by the bacteria (Munita and Arias, 2016). Another contributing 
factor to bacterial resistance is the decrease in compliance amongst 
patient due to the side effects associated with antibiotic use, such as 
diarrhoea, vomiting, urinary tract infections, rashes, candidiasis and 
severe headaches (Ventola, 2015).  
Staphylococcus aureus (S. aureus) is a gram-positive, round and non-
motile bacteria that has become one of the major pathogenic bacteria to 
affect humans worldwide. S. aureus contributes to a wide variety of 
conditions such as scalded skin syndrome, impetigo, cellulitis, septic 
arthritis, osteomyelitis, prosthetic device infections, infective endocarditis, 
pneumonia, food poisoning, meningitis and toxic shock syndrome (Taylor 
and Unakal, 2017). Escherichia coli (E. coli) is a rod-shaped, gram-
negative facultative anaerobic bacterium. Most E. coli strains form part of 
the normal flora of the gut (Lim et al., 2010) but pathogenic E. coli strains 
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can cause urinary tract infections (UTIs), diarrhoeal diseases, colitis, 
bacteraemia, pneumonia, meningitis and peritonitis (Blount, 2015). 
Penicillin has been used to treat S. aureus successfully for many years 
until the bacteria started to adapt and evolve as it became resistant. Once 
penicillin was no longer effective, S. aureus infections were treated with 
methicillin, similar to penicillin, but around 1961, S. aureus began 
developing a resistance to β-lactam antibiotics, including methicillin, giving 
rise to methicillin resistant S. aureus (MRSA). MRSAs first line of 
successful treatment is vancomycin which is a glycopeptide antibiotic that 
prevents the biosynthesis of cell walls (Gilboy, 2011). E. coli infections 
were successfully treated with a wide variety of antibiotics such as β-
lactams, fluoroquinolones, aminoglycosides and trimethoprim-
sulfamethoxazole, but due to their over prescription, E. coli has begun 
developing strains resistant strains to fluroquinolones and third and fourth 
generation cephalosporins (Rajivgandhi et al., 2018). 
Additionally, the rate at which new antibiotics are developed has 
significantly dropped requiring new therapeutic approaches for the 
treatment of illnesses caused by bacteria (Allen et al., 2014). Hydrastis 
canadensis contains the alkaloids berberine and hydrastine that has been 
shown to have antiseptic, anti-inflammatory, anti-cancer and anti-microbial 
properties (Garrett, 2009). It has the ability to improve immune cells ability 
to identify and destroy infection causing organisms (Wu et al., 2018).  
1.2 Aim of the study 
The aim of this study is to investigate the potential antimicrobial effect of 
Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture on S. aureus and E. coli reference strains, by means of the Kirby-
Bauer Disk Diffusion Susceptibility method and the Microdilution method to 
determine the Minimum Inhibitory Concentration (MIC). 
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1.3 Objectives of the study 
The objective of this study was to determine if Hydrastis canadensis 
proves to have antimicrobial effects against S. aureus and E. coli 
reference strains, and also to determine at which concentrations the 
treatment would be most effective. 
1.4 Hypothesis  
It was hypothesised that both the herbal extract and homeopathic mother 
tincture of Hydrastis canadensis would display antimicrobial effects 
against S. aureus and E. coli by inhibiting the growth of the organisms on 
solid and in liquid culture media.  
1.5 Null Hypothesis  
It was hypothesised that both the herbal extract and homeopathic mother 
tincture of Hydrastis canadensis would not display antimicrobial effects 
against S. aureus and E. coli by not inhibiting the growth of the organisms 
on solid and in liquid culture media. 
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CHAPTER TWO 
2.  LITERATURE REVIEW 
2.1 Staphylococcus aureus  
 2.1.1 Identification, classification and morphology of S. aureus 
Staphylococcus aureus (S. aureus) is a round, gram-positive and non-
motile bacteria, with 1mm in diameter colonies (Mamza et al., 2016). S. 
aureus stains a purple colour when a gram stain is applied. It arranges in 
the shape of clusters often resembling a “grape-like” appearance (figure 
2.1 left side). These organisms can grow in up to 10% salt and their 
colonies are yellow or golden as aureus is derived from the Latin word 
aurum meaning golden or yellow (figure 2.1 right side). S. aureus can 
grow anaerobically (facultative) or aerobically at temperatures between 
18˚C and 40˚C but grows optimally at 37˚C (Taylor and Unakal, 2017). S 
aureus is haemolytic on blood agar which demonstrates its ability to kill 
red blood cells within its host as well as develop a large yellow colony 
when on a rich medium (Todar, 2012).  
Figure 2.1 Photo of S. aureus cells after gram staining (left; Taylor and 
Unakal, 2017) and growing agar media showing the 
characteristic golden or yellow color (Vitko and Richardson, 
2013). 
S. aureus has the ability to escape the innate immune response of its 
affected host, therefore evading rapid elimination. The pathogenesis of S. 
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aureus includes the production of several toxins such as, the two-
component barrel forming toxin that has the capabilities of disintegrating 
immune cells of the host and producing toxic enzymes that has the ability 
to destroy tissue such as hyaluronidase, protease, lipase, adhesins and 
surface proteins linked to virulence (Guerra et al., 2017).   
2.1.2 Prevalence of S. aureus infections 
S. aureus is the most prevalent pathogenic bacteria, occurring most 
frequently amongst inpatients in hospitals in the United States and is the 
second most prevalent pathogenic bacteria to affect outpatients (Naber, 
2009). In North America, S. aureus is responsible for more deaths than 
influenza and human immunodeficiency virus (HIV) combined per year. 
Skin and soft tissue infections are common throughout the world and have 
always been treatable until recent years, where multiple patients have 
experienced the spread of such an infection causing sepsis and 
bacteraemia that can be life threatening. Once S. aureus disseminates to 
the blood stream, mortality rates of approximately 30% are reported, 
making it one of the most serious infections throughout the world 
(Surewaard et al., 2016).  
2.1.3 S. aureus infections 
S. aureus is one of the most common causes of infections that appear 
after an injury or an operation (Naber, 2009). S. aureus can be transmitted 
by air droplets and being exposed to an environment where objects have 
been contaminated by the bacteria. S. aureus can commonly be found in 
the nose, throat and on the skin of 30% of individuals (Strommenger et al., 
2018). S. aureus can also gather on medical devices within the body, such 
as catheters, pacemakers and prosthetic joints or valves (Bush and 
Schmidt, 2018). However, S. aureus can cause Staphylococcal scalded 
skin syndrome (SSSS), pneumonia, osteomyelitis and infective 
endocarditis (Denis, 2017). Summary of the various types of infections 
caused by S. aureus are shown in table 2.1.  
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CONDITION SIGNS & SYMPTOMS PREVALENCE DIAGNOSIS TREATMENT REFERENCES
Staphylococcal Scalded 
Skin Syndrome (SSSS)
A major life threatening skin 
infection that results in 
exfoliative toxins being 
released by the 
staphylococcus aureus 
bacteria causing wide 
spread erythema, significant 
superficial blistering and 
shedding of the skin in 
layers. 
                                                                   
Other names: Staphylococcal 
necrolysis of epidermis, Lyell 
disease and Ritter disease.
                                                                              
• Generalised sandpaper-like 
red macular rash that 
progresses into erythema 
with blistering and oedema
• Wrinkled and bullous skin
• Periorbital scabbing and 
facial oedema
• Shedding of the skin at 
friction zones
• A positive Nikolsky sign, 
slight pressure on the skin 
results in exfoliation, leaving 
the superficial layers of the 
skin shiny, red, and wet
                                                                                                                                                                                                                                                   
• Significantly high risk: 
Neonates and children under 
the age of 5 (under 
development of their immune 
and renal systems)
• Inadequate hygiene and 
infection control 
• Poor immunity to 
Staphylococcus aureus 
toxins (immune 
compromised)
• Chronic kidney disease or 
failure (impaired renal 
clearance)
• Characteristic rash
• A skin biopsy:  superficial 
intraepidermal cleavage into 
the granular layer without 
necrosis and with the 
superficial dermal layer 
showing minimal 
inflammatory infiltrates 
• Blood and urine samples 
as well as swabs of the 
throat, nose and skin may be 
used for culture testing 
                            
• First line of treatment is 
penicillinase-resistant beta 
lactam agents (Oxacillin, 
nofacillin ect)
• No response: Vancomycin 
• Topical creams to limit 
colonization of bacteria            
• Fluid and electrolyte 
replacement, temperature 
regulation, sterile lesion 
dressing, prevention of 
secondary infections and 
analgesics for pain 
management are also 
included
• Corticosteroids are 
contraindicated
                                                       
• Dudley and Parsh, 2016                                           
• Kouakou et al ., 2015                                 
• Meshram et al ., 2018                                                   
• Mishra et al ., 2016                                                          
• Staiman et al ., 2017                                                                                                 
                                                                           
Nosocomial pneumonia
An infection of the lung 
parenchyma of the lungs that 
affects hospitalised patients 
48 hours after admission.
Two types include: Ventilator-
associated pneumonia (VAP) 
and hospital-acquired 
pneumonia (HAP). 
The most common bacteria’s 
responsible for nosocomial 
pneumonia are 
Staphylococcus aureus , 
Streptococcus pneumonia , 
Enterobacteriaceae, 
Pseudomonas aeruginosa , 
Escherichia coli  and 
Acinetobacter baumannii.
                                                                                                                                                                   
• Fever > 38˚C 
• Purulent phlegm (wet 
cough)
• Diminished oxygenation 
• Tachypnoea (fast breathing) 
• Abnormal examination of 
chest                                        • 
Suspected in hospitalised 
patients who suddenly 
develop respiratory 
symptoms or in ventilated 
patients when hypoxemia 
worsens with tracheal 
secretions 
• Other: fatigure, difficulty 
breathing, chest pain, chills, 
malaise, confusion
• 1.6 to 3.61  cases per 1000 
admissions 
• VAP occurs in 5-67% of 
ventilated patients
• Risks include: Smoking, 
malnutrition, old age, 
antimicrobial therapy, 
previous nosocomial 
pneumonia, nebulization, 
chronic pulmonary disease 
 

                                                                                                                                                                     
• Chest X-ray: new or 
progressive lung infiltrates
• Full blood count: elevated 
inflammatory makers( white 
blood cells and C-reactive 
protein)
• Sputum culture: pathogen 
identification
• Respiratory infection 48 
hours after admission
                                
• Recommended duration of 
treatment: 7-8 days with re-
evaluation
• First line: linezolid or 
Vancomycin
• Resistant strains: 
piperacillin-tazobactam, 
cefepime, levofloxacin or 
meropenem  
                                              
• Frantzeskaki and Orfanos, 
2018                                                       
• Kalil et al ., 2016                                                           
• Leone et al ., 2017                      
• Russell et al ., 2016                         
• Sopena et al ., 2014                                              
Table 2.1:  Summary of the various types of infections caused by S. aureus 
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Osteomyelitis (OM) 
Infection predominately 
affecting the bone marrow, 
adjacent osseous structures 
with soft tissue involvement.  
OM can be contracted from 
bacteria travelling through the 
blood stream to the bone 
marrow, bacteria spread 
from surrounding tissue or 
due to trauma that allows 
bone exposure to the 
environment. 
                                                                                                                              
• Commonly affects long 
bones in the arms and legs, 
bones in the pelvis and spine 
• Deep pain
• Muscular spasms at 
inflammation zone 
• Fever  
• Weight loss                                   
• Localised warmth, swelling 
and oedema 
• Tenderness                                
• Chronic OM: intermittent 
bone pain (months-years), 
tenderness and sinus 
draining 
                                                      
• Incidence ranges from 2-
16% after an open fracture 
•  Acute osteomyelitis occurs 
in 8 cases per 100 000 
children per year and in 50% 
of cases in children under 5 
• Risks include: Intravenous 
drug use, surgery, trauma, 
immunocompromised,  
malignancy, autoimmune 
disease, malnutrition, 
increased age, hepatic or 
renal failure, smoking, 
diabetes mellitus 
                                                                                                               
• Full blood count: higher 
than normal white blood cell 
count (response to bacterial 
infection)
• Confirmatory diagnositic 
tool: bone biopsy - bone 
sequestra and soft tissue 
sampling for histological 
analysis and causative 
organism identification
• MRI will reveal abscess 
formation, bone marrow 
oedema and peripheral 
enhancement 
                 
• Surgery may be indicated in 
abscess formation or 
necrolysis of bone and soft 
tissue  
• First line of treatment: 
oxacillin, flucoxacillin or 
cephalosporin
• In acute OM (2 weeks or 
less) treatment includes: 
cefapime, nafcillin or 
vancomycin
•  In chronic OM (more than 3 
months) treatment includes: 
vancomycin, ampicillin or 
piperacillin 
                                         
• Arias et al ., 2015                                               
• Bhowmik et al ., 2018                                                        
• Chiappini et al ., 2016                                                         
• Desimpel et al ., 2017                                             
• Gomes et al ., 2013                                                          
• Lima et al ., 2014            
                                                                       
Infective endocarditis                                                                      
                                                                       
Pathogenic bacteria or 
fungus enters the 
bloodstream and adheres to 
the inner lining of the heart 
(endocardium), usually 
affecting the valves of the 
heart. The aortic or mitral 
valves are the most 
commonly affected. 
                                                                                              
• Fatigue
• Shortness of breath
• Hand or feet swelling
• Painful lesions on the 
fingers or toes
• Stroke
• New or worsening murmur
• Heart failure
• Enlarged spleen
• Abnormal spots on hands 
and feet (Splinter 
haemorrhages)                         
                                                                                    
• Incidence ranges from 3-10 
per 100 000 in USA                             
• There are approxiately 40 
000-50 000 new cases 
reported per annum                        
• Risks include: 
immunosuppression (HIV), 
prosthetic valve replacement, 
intravenous drug use, 
heamodialysis, diabetes 
mellitis, congenital heart 
disease  
                                                                                                             
• Transesophageal 
echocardiography is the 
most accurate and key tool. It 
shows the characteristic 
endocardial lesions 
associated with the disease                                      
• Ultrasound of the heart 
(echocardiogram) may 
indicate infection of the heart 
valves                                                                            
• Blood cultures conducted 
for causative microbial 
diagnosis with antibiotic 
sensitivity testing 
                              
• First line of treatent that has 
shown 77-100% cure rates 
are a combination of oral 
ciprofloxacin, rifampin and 
linezolid                                                                                  
• Infected heart valves can be 
surgically replaced or 
repaired especially if heart 
problems occur                                                                                          
• At risk patients should 
practice good oral hygiene 
(Brush teeth, regular check 
ups) to avoid bacteria 
entering the blood through 
the mouth 
                       
• Al-Omari et al ., 2014                                              
• Cahill et al ., 2017                                                        
• Chu, 2018                                                         
• Liesman et al ., 2017                                             
• Xu et al ., 2016                                   
Table 2.1 continued:  Summary of the various types of infections caused by S. aureus 
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 2.1.4  Treatment of S. aureus 
In recent years, the access to effective antibiotics have become a global 
concern due to the rapid emergence of resistant strains, approximately 
over 214 000 neonatal sepsis deaths and 700 000 global deaths have 
occurred due to the increase in antimicrobial resistant bacterial strains 
(Rong et al., 2017). 
According to Mandal (2013), the primary treatment of choice for an S. 
aureus infection would be penicillin. Penicillin treated S. aureus 
successfully for many years until the late 1940’s, when the bacteria started 
to adapt and evolve as it became resistant (Gilboy, 2011). Most countries 
have now developed S. aureus resistant strains to penicillin due to the 
production of penicillinase, an enzyme that destroys the antibiotic (Mandal, 
2013). Once penicillin was no longer effective, clinicians began treating 
S.aureus infections with methicillin which is similar to penicillin, but around 
1961, S. aureus began developing a resistance to beta-lactam antibiotics 
such as methicillin giving rise to Methicillin-resistant S. aureus (MRSA).  
Resistance to methicillin occurs through the S. aureus strain acquiring 
mecA or mecC genes. The mecA gene alters the penicillin-binding protein 
causing a reduced affinity for all beta-lactam antibiotics (Boswihi and Udo, 
2018). The major and rare side effect of penicillin would be 
hypersensitivity reactions (anaphylaxis) associated with administration as 
1-5 per 10 000 cases experience a true penicillin allergy. Other side 
effects include: nausea and vomiting, oedema of the larynx, urticarial and 
itching of the skin, wheezing and collapsing of the cardiovascular system 
(Bhattacharya, 2010).  
MRSA first line of successful treatment is vancomycin (Gilboy, 2011). 
Vancomycin is a glycopeptide antibiotic that prevents the biosynthesis of 
cell walls, however S. aureus has demonstrated an increasing amount of 
resistance to vancomycin known as Vancomycin intermediate-resistant S. 
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aureus (VISA) since the 1990s. S. aureus strains with complete resistance 
to vancomycin are known as Vancomycin-resistant S. aureus (VRSA), 
which was first discovered in 2002 in the United States. Although VRSA is 
limited, there are approximately 14 cases to date in the U.S (McGuinness 
et al., 2017). The side effects associated with the use of vancomycin 
include: low blood pressure (hypotension), interstitial nephritis, fever and 
chills, abnormally low neutrophil count (neutropenia), hypersensitivity 
reactions such as anaphylaxis and red man syndrome, poisoning of the 
ear (ototoxicity) and toxicity of the kidneys (nephrotoxicity) (Bruniera et al., 
2015).   
2.1.5 Alternative treatment of S. aureus  
With the increase in disease in today’s society, the popularity of alternative 
methods of treatments is growing vastly. Homeopathic remedies are now 
being viewed as good substitutes for antibiotics in comparison to allopathic 
medication that weakens the immune system and contributes to the 
growing antibiotic resistant organism crisis (Memon et al., 2018) 
According to Zaman et al. (2016) eight homeopathic mother tinctures were 
tested against S. aureus, Streptococcus pyogenes (S. pyogenes) and 
Pseudomonas aeruginosa (P. aeruginosa) with povidone iodine by Disk 
Diffusion method. The following homeopathic tinctures were used: Arnica 
montana, Baptisia tinctoria, Berberis aquifolium, Berberis vulgaris, 
Calendula officinalis, Echinacea angustifolia, Rhus glabra and Thuja 
occidentalis. The results showed that seven out of the eight tinctures 
displayed antimicrobial activity, where Berberis vulgaris displayed the 
maximum antimicrobial activity with a zone of inhibition of 21.3 mm against 
S. aureus as well as moderate antimicrobial effects seen with Arnica 
montana, Baptisia tinctoria and Berberis aquifolium against S. aureus. 
An in-vitro study was conducted on the antimicrobial effects of six 
homeopathic remedies in 200c potencies and their respective mother 
tinctures with four allopathic antibiotic medicines: penicillin, oxacillin, 
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ciprofloxacin and Augmentin against S. aureus by the Kirby-Bauer Disk 
Diffusion method. The homeopathic remedies included: Atropa 
belladonna, Arnica montana, Nux vomica, Sulphur, Calendula officinalis 
and Berberis vulgaris. The results showed that Augmentin was most 
effective at inhibiting growth of S. aureus whereas all other antibiotics 
showed resistance. All mother tinctures used showed no inhibition 
however Atropa belladonna, Arnica montana, Nux vomica, Sulphur and 
Berberis vulgaris displayed inhibition to S. aureus with zones ranging from 
5-8 mm (Memon et al., 2018). 
2.2 Escherichia coli 
2.2.1 Identification, classification and morphology of E.  coli 
Escherichia coli (E. coli) are a rod-shaped, Gram-negative facultative 
anaerobic bacterium (figure 2.2; Lim et al., 2010). E. coli belongs to the 
Enterobacteriaceae family and can be further classified with the Gamma 
proteobacteria class. E. coli has the ability to replicate within 20 minutes 
and under optimal growth conditions, grows rapidly. In 1997 the E. coli 
genome sequence analysis was initially reported, today there are currently 
more than 48 000 E. coli identified genome sequences (Jang et al., 2017).  
Figure 2.2 Photo showing the typical rod shape of E. coli (Blount, 2015). 
E. coli forms well marked edges of convex, smooth and circular colonies 
when applied on broth nutrient agar. It produces flagellum, which allows 
for its excellent mobility. E. coli contains virulence factors that helps 
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distinguish normal gut flora organisms from those that are pathogenic 
(Goldwater and Bettelheim, 2016).  
2.2.1.1 Types of E. coli 
E. coli strains can be divided into diarrhoeal and extra intestinal pathogens 
resulting in various infections such as septicaemia, meningitis and urinary 
tract infections affecting both animals and the human populations. Extra 
intestinal E. coli (ExPEC) is associated with neonatal meningitis, 
nosocomial bacteraemia, respiratory and urinary tract infections 
(contracted in hospital). Diarrheagenic E. coli (DEC) is classified as the 
most common cause of diarrhoea and consists of various virulence factors 
and phenotypic traits and can be subdivided into 6 categories such as: 
Enteropathogenic, Enterohemorrhagic, Enteroinvasive, Enterotoxigenic, 
Enteroaggregative and diffusely adherent E. coli (Jafari et al., 2012). 
• Enteropathogenic E. coli (EPEC): is the leading cause of diarrhoea 
associated with infants, affecting infants within developing countries 
and contributes to high mortality and morbidity. It attaches to the 
intestinal epithelial cells surface and causes excessive water and 
electrolyte loss resulting in dehydration and eventually death. It has 
been reported that EPEC interferes with the ion channels and 
transporters as well as interfere with the tight junctions of intestinal 
cells causing rapid diarrhoea. This occurs due to rapid and increased 
intestinal secretion with decreased absorption of solutes and ions 
(Singh and Aijaz, 2016). 
• Enterohemorrhagic E. coli (EHEC): This is a form of Shiga-toxin 
producing E. coli (STEC) resulting in severe infections such as 
haemolytic-uremic syndrome, haemorrhagic colitis, non-bloody and 
bloody diarrhoea (Delannoy et al., 2013). It is estimated that 75% of 
EHEC outbreaks are due to consuming contaminated products derived 
from bovine origin (Nguyen and Sperandio, 2012).  
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• Enteroinvasive E. coli (EIEC): EIEC strains have the ability to invade 
the colonic mucosa of humans by penetrating epithelial cells of the 
colon. It then multiplies intracellularly and migrates to adjacent cells 
leading to inflammatory destruction of the intestinal epithelial barrier. 
This process leads to mucus, blood and leukocytes in the stool known 
as dysentery syndrome. The clinical manifestations of EIEC closely 
resemble Shigella but are more severe. EIEC invades macrophages 
and results in macrophage cell death causing a huge inflammatory 
response (Pasqua et al., 2017).  
• Enterotoxigenic E. coli (ETEC): ETEC is one of the major causes of 
excessive diarrhoea and death in children below the age of 5 years in 
developing countries and contributes to excessive diarrhoea amongst 
travellers. The ETEC toxin adheres to receptors of epithelial cells within 
the small intestines and causes water and salt loss in the lumen, 
resulting in diarrhoea (Sahl et al., 2015).  
• Enteroaggregative E. coli (EAEC): After Enterotoxigenic E. coli (ETEC), 
EAEC is the second common cause of diarrhoea in travellers in 
developing and developed countries. EAEC causes watery diarrhoea 
that may be associated with blood or mucus. The features of EAEC 
include intestinal mucosa colonization, development of a mucoid 
biofilm and the formation of various cytotoxins, enterotoxins and 
inflammation of mucosa (Jafari et al., 2012).  
• Diffusely adherent E. coli (DAEC): DAEC is the least common type of 
all strains. DAEC strains cause diarrhoea in children around 18months 
to 5 years of age, urinary tract infections and complications associated 
with pregnancy. It may also form part of the normal intestinal flora 
associated with good gut bacteria in adults and children (Servin, 2014).   
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2.2.2 Prevalence of E. coli infections  
According to Kang et al. (2012) the risk factors associated with the 
contraction of an E. coli infection include: 
• Children, particularly below the age of 5 are at a higher risk for E. coli 
infections due to their developing immune systems. 
• Immune compromised (weak immune system) individuals such as 
those with HIV/AIDS and those undergoing chemotherapy are at 
greater risks as well as the elderly. 
• Eating foods derived from animals (particularly bovine), especially if 
undercook. Raw milk and cheese products are also susceptible to 
being contaminated with E. coli. 
• People exposed to contaminated water for drinking, water polluted by 
human or animal waste or water that has been standing for extended 
periods of time without circulation or disinfecting systems. 
• Lack of personal hygiene such as hand washing can transmit infection 
to and from multiple individuals. 
• Reduction in the levels of stomach acid increases the risk of 
contracting an E. coli infection as the bacteria may survive below 
normal acid levels.  
2.2.3 E. coli infections  
Most E. coli bacterial strains harmlessly colonize animal and human 
gastrointestinal tracts and form part of the normal flora of the gut (Lim et 
al., 2010). Over time, E. coli strains have been acquiring virulence genes 
resulting in pathogenic E. coli strains. The most common route of 
transmission of E. coli infections are through consumption of contaminated 
water and food, but may also be transmitted from person to person or from 
animal to person (Lim et al., 2010). In severe cases it may produce bloody 
diarrhoea, dehydration, kidney failure, blood in the urine, a decreased 
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urine output, bruising and pale skin (Pietrangelo, 2017). Antibiotic 
resistance in E. coli infections are increasing rapidly especially towards 
fluroquinolones and third and fourth generation cephalosporins 
(Rajivgandhi et al., 2018). The conditions produced by E. coli include 
urinary tract infections (UTIs), diarrhoeal diseases and meningitis (Blount, 
2015). Summary of the various types of infections caused by S. aureus 
are in table 2.2. 
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CONDITION SIGNS & SYMPTOMS PREVALENCE DIAGNOSIS TREATMENT REFERENCES 
                                                             
Diarrhoea                          
                                                                
Classified as the frequent 
passage of loose stools 
associated with the quick 
need to evacuate (urgency). It 
is best described as the 
passage of 3 or more 
unformed with a lack of 
consistency stools in a 24 
hour period.                             
Diarrhoea can be classified 
as acute (< 14days), 
persistent (> 14 days) and 
chronic (> 4 months). 
Chronic diarrhoea can be 
further classified into water, 
inflammatory or fatty.                                                                                        
Diarrhoea has become the 
most common infectious 
disease causing mortality 
and morbidity in childhood                
3 or more abnormally 
appearing stools such as 
watery, loose, bloody or 
mucus filled in a 24 hour 
period accompanied by at 
least one of the following:
                                                     
• Vomiting
• Nausea
• Abdominal pain
• Fever > 37.2˚C 
                                                                        
• China, one of the 15 highest 
incidences, with approxiately 
770 million cases of 
childhood diarrhoea annually                                             
• Diarrhoea is resposible for 
2.6 million global deaths 
mostly affecting African 
children below 5
• Recent reports show a 
decrease in child mortality 
due to education and practice 
of oral rehydration therapy 
and breastfeeding during 
episodes 
• Risks include: poor 
sanitation, lack of personal 
hygiene, inadequate water 
supply, poor water storage 
practices, lack of education, 
overpopulation and 
overcrowding, unrefrigerated 
storage of food, age 5 and 
below 
                                                       
• Stool and/or vomit sample 
for bacterial culturing to 
identify organism with 
microscopy and may include  
antigen and 
immunofluorescent testing           
• Sensitive testing can be 
conducted to samples 
obtained to determine 
antibiotic prescription 
                                                       
• First line of treatment would 
be oral rehydration therapy to 
replenish lost electrolytes                                       
• Prebiotic and probiotic 
recommended ro replenish 
good bacteria to ensure 
optimal gut health                    
• Fluoroquinolones such as 
ciprofloxacin or levofloxacin 
are primary treatments for 
diarrhoea                                       
• The combination of 
antibiotics with loperamide 
shortens the duration of the 
illness 
                                                                                                                                                           
• Bossi et al ., 2018                                               
• Kapwata et al ., 2018                                                       
• Onanuga et al ., 2014                                                       
• Riddle et al ., 2016                                                
• Sweetser, 2012                      
• Zhou et al ., 2018
Table 2.2 Summary of the different types of infections caused by E. coli  
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Urinary tract infection (UTI)                          
                                                                
Term to collectively classify 
any infecton involving any part 
of the urinary tract including 
the kidneys, ureters, bladder 
and urethra. The urinary tract 
can be divided into a lower 
tract (bladder and urethra) 
and an upper tract (kidneys 
and ureters).                                                                
UTI’s are caused by both 
gram positive and negative 
bacterial organisms but the 
most common causative 
organism for UTI’s is 
uropathogenic E. coli 
(UPEC) strains.
                                                                                                                                                                                  
• Burning pain on urination 
(Dysuria)
• Passing small amount of 
urine even though there is a 
constant desire to urinate 
(Urinary frequency)
• Sudden urge to urinate 
(Urgency)
• Leakage of urine 
(Incontinence) 
• Blood in the urine 
(Haematuria)
• Foul smelling, cloudly 
and/or dark urine
• Pain above pubic 
symphysis
• Fever: may indicate serious 
infection such as 
pyelonephritis (inflammation 
of the kidneys) also known 
as a kidney infection 
                                                                                                                                                                 
• Incidence in males below 
50 years are low in 
comparison to women being 
30 times more likely to occur 
than men
• 40% of women will 
experience a UTI in their lives
• 1 in 3 women experience 
their first UTI by 24 years of 
age and is commonly seen 
in sexually active women 
• Risks inculde: female 
gender, sexually active 
women, previous UTI's, 
vaginal infection, diabetes 
mellitus, obesity, genetics, 
multiple partners, pre- and 
post coitus voiding, wiping 
technique, wearing tight 
underwear, deferred voiding 
habits, menopause, 
pregnancy 
                              
• UTIs are diagnosed by 
urinalysis showing the 
presence of leukocyte 
esterase, red blood cells and 
increased nitrite levels 
accompanied by classical 
symptoms of a UTI
• Bacteriological urine culture 
to identify the causative 
organis with antibiotic 
susceptibility testing for 
antibiotic prescription 
                                          
• First line of treatment 
includes 3 g single dose of 
fosfomycin trometamol with 
pivmecillinam, nitrofurantoin, 
sulfamethoxazole and 
trimethoprim 
• Alternative therapies 
include, prulifloxacin, 
levofloxacin and ciprofloxacin
 
• Al-Badr and Al-Shaikh, 2013                                               
• Barber et al ., 2013                                                    
• Bartoletti et al ., 2016                                                   
• Flores-Mireles et al ., 2015                                              
• Kranz et al ., 2018                                          
• Tan and Chlebicki, 2016          
• Torpy et al ., 2012
Table 2.2 continued Summary of the different types of infections caused by E. coli. 
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Neonatal meningitis                         
                                                                
Meningitis can be described 
as acute inflammation of the 
meninges that surrounds the 
brain, brain vasculature and 
subarachnoid space due to 
an infection. Neonatal 
meningitis can classified as 
the presence of signs and 
symptoms of infection with 
isolation of the organism 
from cultured cerebrospinal 
fluid (CSF) after birth. 
Neonatal meningitis is most 
commonly caused by Group 
B Streptococcus (GBS) and 
Escherichia coli . 
Microorganisms multiplies 
within the subarachnoid 
space and releases 
endotoxins that give rise to 
an inflammatory response 
that could potentially result in 
neurological morbidity.
                                                                                                                                                                                                                                                                                                                                                                           
• Signs and symptoms are 
usually nonspecific and 
extremely subtle.
• Bulging fontanels, 
convulsions, nuchal rigidity 
usually an indication of a 
misdiagnosis resulting in 
poor outcomes                                           
Other signs and symptoms:
• Irritability 
• Respiratory distress
• Poor feeding or vomiting          
• Temporary cessation of 
breathing (Apnea)
• Abnormally slow heart beat 
and hypotension                          
• Seizures and convulsions        
• Jaundice
• Diarrhoea 
                                                                                                                                                                                                                                                                                                                                                                   
• Incidence ranges from 0.1-
0.4 neonates per 1000 live 
births with a greater 
incidence in long term 
hospitalised infants and 
those born prematurely
• 10% of infants pass away 
from bacterial meningitis and 
20-50% overcome the 
infection but develop 
cognitive and motor 
abnormalities, seizures 
and/or visual and hearing 
impairments
• Risks include associated 
with poor clinical outcomes 
include: presence of 
seizures, coma, hypotension, 
respiratory distress, low 
glucose levels in CSF, 
leukopenia or 
thrombocytopenia and a 
delay in initiation of antibiotic 
therapy 
 
• Diagnosis based on 
culturing cerebrospinal fluid 
(CSF). The CSF is obtained 
through a lumbar puncture. It 
is analysed for cell counts, 
protein levels, glucose levels 
and identification of the 
causative bacteria 
• Neonatal meningitis 
caused by E. coli , Klebsiella , 
listeria monocytogenes  and 
GBS are treated with 
ampicillin with cefotaxime or 
aminoglycoside                             
• In late onset meningitis, 
treatment is aimed at 
prescribing 
antistaphylococcal antibiotics 
such as vancomycin or 
nafacillin with ceftazidime or 
cefotaxime or without 
aminoglycosides 
• Gordon et al ., 2017                                               
• Hunt, 2017                                                   
• Ku et al. , 2015                                               
• Mathur et al ., 2015                                           
• Tan et al ., 2015                                           
Table 2.2 continued Summary of the different types of infections caused by E. coli. 
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2.2.4 Treatment of E. coli  
E. coli infections were successfully treated with a wide variety of antibiotics 
such as β-lactams, fluoroquinolones, aminoglycosides and trimethoprim-
sulfamethoxazole, especially if community and hospital acquired. Due to 
the over prescription, E. coli began developing resistant strains to β-lactam 
antibiotics especially cephalosporins and β-lactam β-lactamase inhibitor 
combinations. The most important contributor to β-lactam resistance is the 
production of β-lactamase, which is a bacterial enzyme that inactivates β-
lactam antibiotics through the process of hydrolysis which causes 
compounds to be ineffective (Ghotaslou et al., 2018). The side effects of 
β-lactam antibiotics includes: Clostiridium difficile (disease of intestines) 
infection, cytopenias (decreased mature blood cells), neurotoxicity, severe 
liver and kidney toxicity (Vardakas et al., 2018).  
The side effects of fluoroquinolones includes: tendinopathy, weakness of 
the muscles, cognitive and autonomic dysfunction, peripheral neuropathy, 
sleep and psychiatric disorders (Golomb et al., 2015). The most common 
side effects seen in aminoglycoside use are vestibular toxicity, hearing 
impairment and injury to the kidneys (Prayle et al., 2010). The side effects 
associated with the use of trimethoprim-sulfamethoxazole include: 
Neurological symptoms such as tremors, delirium and meningitis, 
haematological abnormalities, structural malformations of the foetus, 
kidney abnormalities, toxic epidermal necrolysis and other hypersensitivity 
reactions (Ho and Juurlink, 2011). 
2.2.5 Alternative treatment of E. coli  
According to Nwabudike (2017) antibiotic prescription should be 
personalised according to the sensitivity of the bacterial organism but is 
often not conducted and contributes to bacterial resistance due to the 
wrong antibiotics being used. Alternative therapeutic approaches are 
growing more desirable especially in circumstances where pregnancy is 
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involved or patients experiencing recurrent infections despite allopathic 
therapy. Two cases presented below display the successful treatment of 
homeopathic medicines in patients with E. coli infections:  
• A 12 month old female patient presented with a recurrent urinary tract 
infection (RUTI) due to increasing E. coli colonies, lasting 4 months. 
The patient had been prescribed various antibiotics but kept relapsing. 
She was given homeopathic Phosphorus and improved with no 
relapsing of the infection over a 3 month observation period. 
• A 36 year old female with a 4 year history of discomfort/painful 
urination (dysuria) with positive E. coli present in her urine was 
prescribed Platinum metallicum and Collibacillinum (homeopathically 
prepared E. coli). She recovered with negative urine samples for E. coli 
and stability over a 10 month observation period (Nwabudike, 2017). 
An in-vitro study was conducted on the antibacterial activity of ten 
homeopathic mother tinctures and ciprofloxacin against 2 gram-positive 
(S. aureus and Bacillus subtillis) and 2 gram-negative (E. coli and P. 
aeruginosa) bacteria’s by Disk Diffusion method. The homeopathic mother 
tinctures used were: Baptisia tinctoria, Berberis aquifolium, Echinacea 
angustifolia, Eucalyptus globulous, Hydrangea arborescens, Hydrastis 
canadensis, Hypericum perforatum, Kreosotum, Pulsatilla nigrican and 
Thuja occidentalis. The results showed that Hydrastis canadensis had the 
maximum zone against P. aeruginosa. Eight out of the ten tinctures 
displayed antimicrobial activity against E. coli specifically Eucalyptus 
globulous with a maximum zone of 17 mm compared to 37 mm seen with 
ciprofloxacin. Hydrangea arborescens and Kreosotum had no inhibitory 
effects on E. coli (Rehman et al., 2018).  
Further research is required to support the use of homeopathic medicines 
as an alternative to antibiotics due to the growing field of homeopathy and 
the positive results seen in existing studies.  
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2.3 Antibiotic resistance 
Antibiotic resistance has become one of the largest threats to the health of 
human beings worldwide (World Health Organization, 2017). The 
combination of large amounts of antibiotics prescribed over many decades 
has resulted in the emerging and increasing risk of bacterial resistance 
(Ventola, 2015). Bacterial resistance to antimicrobial drugs occurs due to 
genetic mutation of the bacteria, acquiring resistance from other bacteria 
or adaptation by the bacteria (Munita and Arias, 2016). The spread of 
multiple antibiotic resistant organisms is becoming more prevalent and 
traditional antibiotics are no longer always effective against the bacterium. 
Additionally, the rate at which new antibiotics are developed has 
significantly dropped requiring new therapeutic approaches for the 
treatment of illnesses caused by bacteria (Allen et al., 2014).  
The function of antibiotics is to kill bacteria or inhibit bacterial growth. 
Antibiotic resistance develops when the bacteria continues to multiply 
even during antibiotic treatment. The bacterium becomes less sensitive to 
the effects of the antibiotics, requiring a higher concentration of the once 
effective drug to administer the same desired effects (Zaman et al., 2017).  
In 2013, according to the Centres for disease control (CDC) humanity has 
entered a “post-antibiotic” era. The continuous increase in bacterial 
resistance will lead to the implementation of previously less effective 
measures such as amputation, debridement, isolation and disinfection 
resulting in longer rates of recovery and treatment time, more invasive 
procedures and less successful outcomes for patients. Previously common 
conditions will no longer be treatable and will result in high mortality and 
morbidity rates amongst populations (Michael et al., 2014). 
2.3.1 Inappropriate antibiotic use 
Antibiotics prescribed in primary care for oral usage is at an estimated 80-
90%. The key function of antibiotics are to kill or inhibit bacteria, it is not 
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indicated for coughs, sore throats and colds associated with viral 
infections and yet a survey conducted in the UK about the prescription of 
antibiotics in general practice found that half of all patients for the above 
mentioned conditions were given antibiotics (Shallcross and Davies, 
2014). 
The public has a constant belief that antibiotics are the first line of 
treatment for any form of ailment, leading to excessive widespread use of 
antibiotics even when not necessary contributing to increasing rates of 
antibiotic and bacterial resistance. Practitioners prescribe antibiotics 
without pathogenic and antibiotic sensitivity testing which causes repeated 
visits and re-prescription of other antimicrobial drugs. It allows the bacteria 
to undergo intense pressure and survive leading to resistant strains 
(Michael et al., 2014). In developing countries most antibiotics are 
available for purchase without the prescription of a qualified general 
practitioner. Due to antibiotics being so easily available over the counter, it 
increases resistance as ill-patients aren’t trained in antibiotic prescriptions, 
its relevant indications and contraindications (Zaman et al., 2017). 
Antibiotics are used in both developed and developing countries as growth 
supplements for livestock. Approximately 80% of antibiotics in the U.S are 
sold for animals, to prevent infection and promote growth. Antibiotic 
ingestion from the meat or by-product of the livestock allows for the 
transfer of resistant organisms which could potentially lead to serious 
health complications (Ventola, 2015).  
2.3.2 Antibiotic compliance  
One of the major contributors to antimicrobial resistance is patient 
compliance. Patients tend to skip doses or stop medication when 
symptoms begin to subside or there is the development of side effects 
associated with the antibiotics. The antibiotic gets stopped before the 
bacteria is destroyed which allows the bacteria to survive sub-therapeutic 
concentrations of the particular antibiotic therefore becoming stronger and 
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increasing the risk of the transmission of resistant strains and antibiotic 
resistance to other forms of antibiotics (Ayukekbong et al., 2017) 
In developing countries struck with poverty, the first line of treatment would 
be traditional healers who prescribe herbal mixtures of unknown 
substances and efficacy. The combination of herbal mixtures, antibiotics 
and supplements given at the intent of improving the patient’s outcome 
could potentially allow the pathogen to become stronger and survive 
treatment as there aren’t studies to support these combinations (Llor and 
Bjerrum, 2014). 
2.4 Homeopathy 
Homeopathy is a form of complementary medicine that was derived from 
the words homoios meaning similar and pathos meaning suffering. 
Therefore, it can be classified as a therapeutic approach where by the 
treatment of disease is based on symptom similarity (Rehman and Ahmad, 
2017).  
2.4.1 History of homeopathy  
Homeopathy was founded by a German physician, Dr Christian Friedrich 
Samuel Hahnemann (1755-1843). He studied at the University of Leipzig 
as a medical student and graduated in 1779. Samuel Hahnemann had a 
knack for languages and used his talents to translate many books from 
languages such as Greek, Latin and English into German as well as 
taught French and German to help financially (Bloch and Lewis, 2008). 
He was disgusted by the methods of medical practice at the time such as, 
bloodletting by leech application or lancing veins. He urged the 
implementation of good hygiene and ventilation, sufficient sleep and rest, 
exercise and a healthy diet into practice for more favourable patient 
outcomes. It was credited that homeopathy was born in 1780, when 
Hahnemann translated Dr William Cullen’s book, A Treatise on Materia 
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Medica. Cullen spoke about Chinchona bark as a form treatment against 
malaria. Hahnemann experimented by ingesting small quantities of the 
bark and recorded each sign and symptom he experienced. He then 
developed malaria-like symptoms after 3 hours of ingestion. His symptoms 
comprised of utter prostration, dehydration and thirst, a fever, heart 
palpitations, a racing pulse and extreme anxiety (Block and Lewis, 2008). 
He thus developed the first principal of homeopathy like cures like (similia 
similibus curentur) meaning, a remedy can cure an illness if the remedy is 
administered in a healthy individual and it produces similar symptoms to 
that of the illness experienced by the patient (Reddy, 2018).  
2.4.2 Law of similars 
The law of similars are one of the first principals of homeopathy developed 
by Samuel Hahnemann. It is a therapeutic approach whereby a condition 
can be treated when the symptoms produced by a sick individual closely 
matches a remedy that can produce the same/similar symptoms when 
administered in a health patient, cure will be initiated (Kuzniar, 2017).   
2.4.3 Single remedy  
A single remedy in homeopathy refers to administering 1 particular remedy 
at a given time. Hahnemann did not believe in giving multiple remedies at 
the same time as it would disrupt the vital force of the patient which is the 
ability of the patient to heal themselves as well as disrupt their recovery 
time and prevent the prescriber from knowing which remedy worked or 
inhibited another. Remedies have different drug pictures, methods of 
preparations and rhythms within the body, mixing various remedy brings 
disharmony to the body. 5 different remedies may be administered during 
the same day as long as each one is administered at their own given time 
and not together (Jonas and Jacobs, 2009). 
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2.4.4 Minimum dose  
The law of minimum dose was discovered by Dr Hahnemann due to the 
harmful effects large doses of medicines had on people and their bodies. 
He began diluting remedies several times accompanied with 
agitation/succession with each dilution (Rehman and Ahmad, 2017). Small 
doses should be administered as it is gentler on the patient and has 
benefits such as prevents side effects and medicinal aggravations, 
produces no organic damage and no addiction. The minimum dose refers 
to the least possible dose which will bring about a cure (Sharma, 2016). 
2.4.5 Proving of homeopathic medicines 
A homeopathic proving is conducted by testing substances on healthy 
individuals of various ages and different sex groups and recording the 
outcomes. The groups of healthy individuals are given a potentized 
remedy (nontoxic, diluted and succussed substance) to be taken regularly. 
The homeopathic remedy will cause physical, psychological and mental 
symptoms to develop and participants are required to record each 
symptom, emotion or feeling experienced in detail. The information 
gathered from each participant becomes the homeopathic remedy picture 
and is entered into the Materia Medica, where it can later be selected to 
closely match a patient’s disease picture that is similar to the remedy 
picture produced by a healthy individual according to the law of similars 
(Riley, 2017). 
2.4.6 Potentization  
Mother tinctures are solutions with a combination of plants (roots, resins, 
wood, bark, fruit, flowers, leaves, seeds and fruits), animals or mineral 
materials added to a specific quantity of solvent (Malik et al., 2013). A 
mother tincture is the starting point and the lowest potency of any 
homeopathic remedy. Mother tinctures are prepared from fresh materials 
rather than dried like with herbal extract preparations. Homeopathic 
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medications are manufactured according to either the homeopathic 
pharmacopeia of the United States (HPUS) or the German pharmacopeia 
(GHP) (Frye, 2003). Mother tinctures are prepared according to 1 part 
fresh material to 9 parts of solvent, which produces 1D potency. The 
pharmacopoeia gives the method of preparation for each homeopathic 
tincture and remedy and solubility in alcohol and water. Plant materials are 
required to be finely chopped and macerated in alcohol to extract the 
active constituents into the solution. It is thereafter filtered to separate the 
left over plant material from the active solution (Ernst, 2016).  
According to Bloch and Lewis (2008) Homeopathy consists of two main 
scales of potencies: 
• Decimal scale (D): meaning the remedy is diluted 10 times. A ‘D’ 
potency is made with 1 part starting material with 9 parts solvent 
(water, alcohol etc.) and violently shaken (Succussion) 10 times, thus 
generating the D1 potency. A D2 potency is prepared by taking 1 part 
of the D1 potency with 9 parts solvent and succussing it a further 10 
times. This process is repeated for successive potencies desired. 
• Centesimal scale (C): meaning the remedy is diluted 100 times. A ‘C’ 
potency is made with 1 part starting material with 99 parts solvent 
(water, alcohol etc.) and succussed 100 times, thus generating the 1C 
potency. A 2C potency is prepared by taking 1 part of the 1C potency 
with 99 parts solvent and succussing it a further 100 times. This 
process is repeated for successive potencies desired. 
If a substance is insoluble in alcohol or water then the method of trituration 
must be followed to make a substance soluble. To prepare an insoluble 
substance, 1 part of the substance must be mixed with 9 or 99 parts of 
lactose in a mortar and pestle and grinded for 1 hour to produce either D1 
or 1C potency. For the next potency 1 part of the D1 or 1C is taken and 
mixed with 9 or 99 parts of lactose and grinded for 1 hour to produce 
either D2 or 2C potency. The remedy becomes soluble after the D6 or 3C 
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potency, therefore the above method can be applied with dilution and 
succussion (Bloch and Lewis, 2008).  
2.5 Hydrastis canadensis  
Hydrastis canadensis belongs to the Ranunculaceae (buttercup) family. 
The common names for Hydrastis canadensis are golden seal, golden 
root, Indian dye, Indian turmeric, jaundice root, orange root, yellow root, 
yellow pucoon, ground raspberry, eyebalm and eyeroot. It is a perennial 
growing from a yellow short rhizome that is herbaceous. This perennial 
grows in spots in rich woodlands, along stream banks and hill slopes. 
Hydrastis canadensis is indigenous to south eastern Canada and eastern 
United States and was used for many decades by Native Americans 
(Pengelly et al., 2012). Figure 2.3 shows the Hydrastis canadensis plant. 
Figure 2.3 Hydrastis canadensis (Golden seal) (Zhou and Sauve, 2006) 
Hydrastis canadensis has been found to treat most infective type 
diseases. Its most powerful feature is its ability to fight infections of any 
kind. The uses of Hydrastis canadensis ranges from, infections of the 
gastrointestinal tract, oesophageal, breast and prostate cancer, respiratory 
tract infections, urinary tract infects and various skin conditions. It is also 
useful in the treatment against a wide variety of gram-positive and gram-
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negative bacteria (Rangineni, 2011). The main alkaloids found in this herb 
are Berberine, Hydrastine and Canadine which produces an astringent 
effect on mucus membranes, decreases inflammation, has antiseptic 
properties which help clear infections as well as anti-diabetic, anti-cancer 
and antimicrobial effects (Garrett, 2009). The specific alkaloid Berberine is 
responsible for the herbs antimicrobial effects. Hydrastis canadensis has 
an immune stimulating property which allows for the prevention of 
infections, it does so by improving the immune cells ability to identity and 
destroy infection causing organisms (Wu et al., 2018).  
Long term usage of Hydrastis canadensis can lead to the killing of both 
good and bad bacteria in the body and high doses may produce diarrhoea, 
dizziness, nervous system effect such as convulsions, paralysis, 
depression, dyspnoea, nephritis and may be fatal. This herb interacts with 
anticoagulants, cardiac medications and CNS depressants (Edwards et 
al., 2015).  
2.5.1 Hydrastis canadensis herbal extract 
Hydrastis canadensis herbal extract is prepared according to the 
percolation extraction method. The root and rhizome obtained from the 
Hydrastis canadensis plant is macerated in a slow moving container with 
the appropriate solvent for 24 hours where the solvent absorbs the active 
compounds present in the roots and rhizomes of the plant. The liquid 
extract is therefore poured out from the bottom of the container (Handa et 
al., 2008). 
2.5.2 Hydrastis canadensis mother tincture 
Hydrastis canadensis mother tincture is manufactured according to the 
HAB 4a method found in the German Homeopathic Pharmacopoeia 
(GHP). This method uses 1 part dried root of the plant chopped finely with 
9 parts 62% ethanol concentration added to it, to form a D1 potency 
(1:10). In order for extraction to take place, the mixture is added to an air-
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sealed container and placed in a dark area at room temperature not 
exceeding 20˚C and shaken occasionally. The mixture is then filter to 
separate the residue from the mother tincture (German Homeopathic 
Pharmacopoeia, 1993).  
2.5.3 Hydrastis canadensis active ingredients  
According to Scazzocchio et al. (2001) the antibacterial activity of 
Hydrastis canadensis extract and its major alkaloids: β-hydrastine, 
berberine, canadine and canadaline were tested against two Gram-
positive strains (S. aureus and Streptococcus sanguis (S. sanguis)) and 
two Gram-negative strains (E. coli and P. aeruginosa). The aim of the 
study was to evaluate the bactericidal (Kill) activity by determining the 
killing time on a low density bacterial inoculum and the bacteriostatic 
(inhibit) activity by means of Minimum Inhibitory Concentration (MIC) in 
liquid medium. The results revealed that, berberine, canadine and 
canadaline are responsible for the extracts antimicrobial activity while β-
hydrastine showed no activity against all organisms for both experiments. 
Berberine displayed bactericidal effects against all organisms except for P. 
aeruginosa, canadaline had stronger effects than berberine on the Gram-
positive bacteria but the same effects against E. coli and canadine showed 
no effects against E. coli. The MIC showed that all alkaloids had 
bacteriostatic effects against Gram-positive bacteria. 
Overall Hydrastis canadensis and its alkaloids have positive antibacterial 
effects and have the potential to be used against various types of bacteria, 
however further research needs to be conducted as there are minimum 
studies available.  
2.5.4 Homeopathic symptom picture of Hydrastis canadensis  
Hydrastis canadensis has an affinity for mucous membranes, causing 
relaxation to them and treats yellowish, thick ropy secretions that burn 
 
 
30 
 
specifically. Characteristics associated with Hydrastis canadensis include 
(Vermeulen, 2015):  
• Yellowish, thick ropy secretions anywhere in the body (nose, throat, 
stomach, urethra and uterus). 
• Weak muscular power. 
• Particularly acts on the stomach: Poor digestion, obstinate constipation 
and has a marked action on the liver. 
• Pre-cancer and cancerous states where pain is removed as a result of 
cancer. 
• Haemorrhagic and catarrhal processes. 
• Sense of raw burning, shallow ulcers. 
• All symptoms accompany an all gone feeling. 
• Antimicrobial effects and immune boosting. 
2.6 Kirby-Bauer Disk Diffusion Susceptibility method  
The Kirby-Bauer Disk Diffusion Susceptibility method measures the effects 
of antimicrobial compounds against various microorganisms. The bacteria, 
which is grown overnight is inoculated (introduced) onto Mueller-Hinton 
agar plates. Various concentrations of the antimicrobial agent are 
impregnated onto filter paper disks and then placed on the agar mediums 
surface. At 35-37˚C, the agar disk which contains the antimicrobial agent 
and inoculated bacteria are incubated for 16-24 hours allowing the 
diffusion of the antimicrobial agent into the agar. This results in the 
concentration of the antimicrobial agent to decrease as the distance 
increases from the disk. The susceptibility of the antimicrobial agent 
against the bacteria is determined by the measurement of the zone of 
inhibition of the bacteria around the disk (Syal et al., 2017). The 
presentation of the measurement of the zone of inhibition can be seen in 
figure 2.4. 
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Figure 2.4 The measurement of zones of inhibition (Acharya, 2013). 
2.7 Microdilution method and Minimum Inhibitory Concentration 
(MIC) 
The Microdilution method can be divided into Agar Dilution and Broth 
Dilution methods to determine the Minimum Inhibitory Concentration 
(MIC). The MIC is lowest possible concentration of an antimicrobial agent 
that produces visible bacterial growth inhibition. Agar Dilution consists of 
various concentrations of the antimicrobial agent incorporated into a 
nutrient agar medium. A standardized number of cells are applied to the 
agar plate surface in comparison to the Broth Dilution method where 
various concentrations of the antimicrobial agent are incorporated with 
liquid growth medium that is inoculated with bacteria. The Broth Dilution 
makes use of a 96 well plate. The plates are incubated for a certain period 
of time, usually 16-20 hours and there after the growth and MIC can be 
assessed (Wiegand et al., 2008).  
This study makes use of the Broth Dilution to determine the MIC. Figure 
2.5 demonstrates an example of a 96-well microtiter plate layout. 
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Figure 2.5 Example of a 96-well microtiter plate (Palumbo et al., 2011).                                  
2.8 Related research  
A study conducted by the School of Pharmacy in Australia tested 21 
hyrdoethanol herbal extracts and 4 essential oils for antibacterial activity 
against Helicobacter pylori and Campylobacter jejuni, Hydrastis 
canadensis was one amongst many active herbal extracts in inhibiting the 
growth of Helicobacter pylori. (Cwikla et al., 2010) 
An in-vitro study conducted by Bandyopadhyay et al. (2013) on the 
antimicrobial effects of berberine, through Broth Dilution and Disk Diffusion 
methods yielded positive results that Hydrastis canadensis can serve as a 
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good antibacterial agent against MDR E. coli (Bandyopadhyay et al., 
2013). 
An in-vitro study was conducted to show the activity of Hydrastis 
canadensis extracts against methicillin-resistant S. aureus (MRSA) 
through MIC methods showed that Hydrastis canadensis had more 
powerful antimicrobial activity than its alkaloid berberine alone. It 
demonstrated inhibition of MRSA toxin production and the mixture of its 
constituent’s acts together against MRSA through various mechanisms. It 
concluded Hydrastis canadensis as a preventive form of treatment against 
infections (Cech et al., 2012). 
An experiment was conducted by Knight (1999) on the effects of Hydrastis 
canadensis on the growth of Streptococcus pyogenes, Pseudomonas 
aeruginosa and S. aureus were compared to the effects of penicillin on the 
same bacterial strains with the use of MIC methods. Results revealed that 
Hydrastis canadensis has inhibitory effects against S. pyogenes and S. 
aureus at high concentrations and penicillin at lower concentrations. Thus 
the findings support the use of Hydrastis canadensis against infections to 
those who prefer herbal medicines as a form of treatment (Knight, 1999). 
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CHAPTER THREE 
3. METHODOLOGY   
3.1 Experimental design  
This quantitative in-vitro control study was conducted at the University of 
Johannesburg, Doornfontein Campus at the Water and Health Research 
Centre (WHRC) under the supervision of a laboratory technician with the 
appropriate qualifications with permission granted (APPENDIX C). 
3.2 Antimicrobial agents 
Hydrastis canadensis mother tincture was obtained from a local, reputable 
supplier. It was prepared according to the HAB 4a method from the 
German Homoeopathic Pharmacopoeia (GHP). This method uses 1 part 
plant material to 9 parts solvent (62% ethanol).  
Hydrastis canadensis herbal extract was obtained from a local, reputable 
supplier. Hydrastis canadensis herbal extract was prepared according to 
the percolation extraction method making use of 1 part dried plant material 
to 5 parts solvent (45% (v/v) ethanol). 
3.3 Stock cultures 
Staphylococcus aureus (S. aureus) (ATCC strain BAA-1026) and 
Escherichia coli (E. coli) (ATCC strains 1175 and 8739) reference strains 
was used for this study. Strains were stored as glycerol stocks at -80°C at 
the Water Health and Research Centre (WHRC) laboratories and grown 
overnight (16-18 hours) on Mueller-Hinton agar plates or in Mueller-Hinton 
broth at 37°C when needed.  
To ensure consistent results bacterial suspension equal to an 0.5 
McFarland standard was used for all experiments. This was achieved from 
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either overnight culture on agar plates (for use with the Kirby-Bauer Disk 
Diffusion test) or in liquid cultures (for use with broth dilution cultures). In 
the case of cultures grown on culture plates the strains were plated onto 
Mueller-Hinton agar plates and allowed to grow at 35°C for 16-18 hours. A 
sterile cotton swab was used to pick a colony from the plate and added to 
a 0.9% saline solution, and adjusted if needed, to create a bacterial 
suspension of 0.5 McFarland.  
To create bacterial suspension from overnight cultures grown in liquid 
broth the strains were grown overnight (16-18 hours) in Mueller-Hinton 
broth at 35°C with mild agitation (150 rpm). The bacterial suspension 
concentration was adjusted to a turbidity equal to 0.5 McFarland standard 
with sterile media. 
3.4 Media preparation  
Mueller Hinton broth was prepared by weighing 4.2 g and dissolved in 200 
ml distilled water (dH2O), Mueller Hinton agar was prepared by weighing 
7.6 g and dissolved in 200 ml of dH2O and poured into sterile petri dishes. 
All media prepared were sterilized by autoclaving at 121°C and 15 P.S.I 
for 1 hour and placed in a water bath at 40-50°C. 
3.5 Kirby-Bauer Disk Diffusion  
Kirby-Bauer Disk Diffusion method is recommended by the Clinical 
Laboratory Standards Institute (Hudzicki, 2009) and the standardised 
protocol was used for the experiments. To create bacterial lawns a 
bacterial suspension equal to a 0.5 McFarland standard was created for 
each strain by adding a bacterial colony with a sterile swab to a 0.45% 
saline solution and adjusting the density to the desired point. A hundred 
microliters of the bacterial suspension was evenly spread onto a Mueller 
Hinton agar plate to form a bacterial lawn, and were then allowed to dry for 
3 to 5 minutes. 
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Sterile disks were impregnated with the Hydrastis canadensis herbal 
extract and Hydrastis canadensis mother tincture and placed onto the 
surface of the agar plates using flame sterilized forceps. Each plate was 
numbered accordingly using a template for the placement of the sterile 
discs before incubation to allow identification and monitoring of the 
progress displayed by each plate as shown in figure 3.1. The plates were 
inverted and incubated at 35°C for 16-18 hours. Following incubation the 
plates were examined for a zone of inhibition of bacterial growth and the 
zone measured in millimetres around the impregnated disks by means of a 
ruler.  
Figure 3.1 Template used for the placement of the sterile discs 
with/without any solvent or compound.  
The experiment was done in triplicate to ensure repeatability and on three 
independent days (reproducibility) to obtain reliable results. Appropriate 
controls, outlined in table 3.1, were included in the experiments to test the 
reliability and reproducibility of the methods. Figure 3.2 shows an example 
of Kirby-Bauer Disk Diffusion Susceptibility Test with relevant controls and 
compounds labeled accordingly.   
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Table 3.1 Controls used with the Kirby-Bauer Disk Diffusion 
Susceptibility and Minimum Inhibitory Concentration tests. 
Control Description 
Empty sterile disc Included to ensure that the discs are sterile and that it 
did not inhibit bacterial growth 
Distilled water Included to ensure that there was no contamination or 
inhibition from the pipettes and water used to prepare 
dilutions 
Solvents Included to test if the solvents used could contribute to 
the inhibition of the bacterial growth. 
Antibiotics Included as method control to show the inhibition 
(positive), or no inhibition (negative), of bacterial growth 
on the plates. This included: 
S. aureus - Streptomycin HLS 300 mcg (positive) and 
Trimethoprim TR 5 mcg (negative) 
E. coli - Streptomycin HLS 300 mcg (positive) and 
Penicillin-G P10 5.6 mcg (negative) 
Figure 3.2 Mueller-Hinton plate showing the Kirby-Bauer Disk Diffusion 
Susceptibility Test with S. aureus bacterial lawn tested with a 
herbal extract that inhibits growth (1), solvent used to make 
the herbal extract (2), empty sterile disc (3), negative 
antibiotic (4), positive antibiotic (5) and distilled water (6). 
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3.6 Microdilution method 
To determine the Minimum Inhibitory Concentration (MIC) of the 
compounds, the compounds were tested by serial dilution method in 96 
well plates. The 96 well plate was labeled and into each well 100 µl 
Mueller-Hinton broth was added. The plate was divided into two and six 
wells per row used for the dilutions as shown in the figure 3.3. The 
compound to be tested (50 µl) was added to the first well, mixed and 50 µl 
removed, added to the next well and repeated for the next four wells. The 
50 µl removed from the sixth well was discarded. Like the method above a 
variety of controls was included into the method. This included a media 
control (no bacteria), a bacteria control (nothing added), test samples, 
solvent controls and antibiotic controls (negative and positive) listed in the 
previous section. 
Figure 3.3 Shows the MIC of compounds tested by serial dilution 
method in 96 well plates. The plate diluted into two and six 
wells per row for dilutions 
A duplicate plate was made, and the plates were incubated at 35°C for 16-
18 hours. After the incubation period 50 µl Iodonitrotetrazolium chloride 
(INT) dye was added to the wells, incubated at 35°C for up to 30 min, to 
produce a pink to dark purple color (Eloff, 1998). 
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It was noted that the color of the tincture influenced the observation of the 
purple color and it was decided to repeat the procedure using a 24 well 
plate with 10 times the original volume of the individual components used 
in the 96 well plates. The 24 well plates were prepared as shown in figure 
3.4 and incubated at 35°C for 16-18 hours in a shaking incubator before 
the addition of the INT to monitor for the presence of viable cells. 
 
 Figure 3.4 Shows the MIC of compounds tested by serial dilution 
method in 24 well plates. The plate diluted into two and six 
wells per row for dilutions 
3.7 Data collection 
Zones of inhibition were measured in millimetres (mm) for each disc on all 
the plates and reported accordingly. The MIC was determined as the first 
well where the Iodonitrotetrazolium chloride (INT) dye was metabolized to 
form a pink to purple color showing viable cells. If the solvent also showed 
bacterial growth inhibition (no color in the wells), the number of wells was 
deducted from the test compound results to reflect the actual impact of the 
compound alone. 
3.8 Data analysis 
Zone of inhibition for the Disk Diffusion test is presented in table format 
showing the average, minimum and maximum measurements obtained. 
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Since the extracts contain two active compounds (berberine and 
hydrastine) and the exact concentration of each compound is not known, 
the data is presented as the last dilution that showed inhibition of bacterial 
growth. The possible effect that the solvent had was not compensated as 
it was only obvious in one experiment. A note is made for the reader to 
take into consideration where the data is presented. 
3.9 Ethical considerations  
The project was approved by the Higher Degrees Committee (HDC-01-47-
2018) and Research Ethics Committee (REC-01-87-2018) of the 
University of Johannesburg (APPENDIX A and B). There were no direct 
ethical considerations relevant to this study. The tests were conducted in a 
controlled laboratory environment. Supervision of this study and 
experiment was conducted by a board-certified laboratory technician from 
the Water and Health Research Centre, who is qualified in doing these 
experiments. The researcher was appropriately trained to conduct the 
experiment and ensured prevention of contamination or exposure to the 
relevant bacterial strains (S. aureus and E. coli). 
All equipment were appropriately cleaned and sterilized before each use 
to avoid contamination and compromised results. All safety protocols were 
adhered to, to ensure laboratory safety, safe removal and disposal of 
bacterial organisms, tinctures, herbal extracts and equipment. Protective 
clothing such as gloves, safety glasses and laboratory coats were worn at 
all times to maintain and ensure safety of the researchers involved. All 
efforts were made to minimize any risks of contamination or exposure to 
bacterial strains, if exposure did occur, prompt adherence to laboratory 
protocols would have been conducted and disposal of bacterial strains 
would have been done according to laboratory health and safety 
regulations. 
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CHAPTER FOUR 
4. RESULTS  
4.1 Introduction  
The aim of the study was to investigate the antimicrobial activity of 
Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture against S. aureus and E. coli reference strains by the use of the 
Kirby-Bauer Disk Diffusion Susceptibility method and to confirm the results 
obtained, the Microdilution method was used in order to determine the 
Minimum Inhibitory Concentration (MIC). The disks used had diameters of 
6 mm and all measurements shown as 6 mm demonstrates no inhibition of 
bacterial growth. The MIC is the lowest concentration at which there is 
bacterial inhibition. The Hydrastis canadensis herbal extract was prepared 
from the roots and rhizomes of the plant in 45% ethanol (EtOH) and the 
Hydrastis canadensis mother tincture was prepared from the dried roots of 
the plant in 69% EtOH. This chapter summarizes and presents the data 
obtained from the experiments that will be discussed in detail in the next 
chapter. 
4.2 Kirby-Bauer Disk Diffusion  
 The Kirby-Bauer Disk Diffusion Susceptibility method, also known as the 
Agar Disk Diffusion method, was the method of choice to test if Hydrastis 
canadensis herbal extract and Hydrastis canadensis mother tincture could 
inhibit bacterial growth of the S. aureus and E. coli strains respectively. 
The zones of inhibition were measured in millimetres (mm). The 
experiment was conducted in triplicate and figures 4.1 and 4.2 show the 
typical results obtained for both compounds and both bacterial strains. 
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Figure 4.1  Mueller-Hinton plates showing the Kirby-Bauer Disk Diffusion 
Susceptibility Test with S. aureus. 
1A) Hydrastis canadensis herbal extract in 45% EtOH, 1B) Hydrastis 
canadensis mother tinctures in 69% EtOH, 2A) 45% EtOH, 2B) 69% EtOH, 
3) empty disc, 4) Trimethoprim TR 5 mcg, 5) Streptomycin HLS 300 mcg 
and 6) distilled water. 
Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture inhibited bacterial growth of S. aureus but the herbal extract had a 
more prominent inhibitory effect with an average zone of inhibition of 12.8 
mm as compared to the mother tincture with an average zone of inhibition 
of 8.2 mm. The 45% and 69% EtOH solvents used for the preparation of 
the herbal extract and mother tincture did not have any effect on the 
bacterial growth with zones of inhibition of 6 mm. 
The controls worked as expected indicating that the data is trustworthy 
with the empty disc, Trimethoprim TR 5 mcg (antibiotic negative control) 
and distilled water controls showing no effects against S. aureus with 
zones of inhibition of 6 mm. The Streptomycin HLS 300 mcg (antibiotic 
positive control) displayed the highest inhibitory effect on S. aureus with 
an average zone of inhibition of 27.6 mm as expected, confirming that the 
test worked. 
  
A B 
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A B 
Figure 4.2 Mueller-Hinton plates showing the Kirby-Bauer Disk Diffusion 
Susceptibility Test with E. coli. 
1A) Hydrastis canadensis herbal extract in 45% EtOH, 1B) Hydrastis 
canadensis mother tincture in 69% EtOH, 2A) 45% EtOH, 2B) 69% EtOH, 
3) empty disc, 4) Streptomycin HLS 300 mcg, 5A) Trimethoprim TR 5 mcg, 
5B) Penicillin-G P10 (5) and 6) distilled water. 
The Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture had no inhibitory effect on E. coli with zones of inhibition of 6 mm. 
The solvent 45% EtOH used to produce the herbal extract did not show 
any bacterial inhibition although the 69% EtOH used to prepare the mother 
tincture had a minor inhibitory effect (figure 4.2 B, disc 2). The 
Streptomycin HLS 300 (antibiotic negative control) showed inhibition in all 
tests and Trimethoprim TR 5 mcg (antibiotic positive control) also inhibited 
the growth of this E. coli strain with an average zone of inhibition of 24 mm 
and it was therefore decided to use Penicillin-G P10 (10 units; 5.6 mcg) as 
an alternative antibiotic negative control to show that the test worked and 
that the results are reliable. The empty discs and discs with distilled water 
had no effect on the growth with zones of inhibition of 6 mm as expected. 
A summary of the results obtained from the experiments conducted in 
triplicates of the Kirby-Bauer Disk Diffusion method are shown in table 4.1 
below. The minimum and maximum zones of inhibition were measured 
(mm) and recorded for each of the experiments done. 
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Zone of inhibition 
 Average  Minimum Maximum 
Staphylococcus aureus 
Hydrastis canadensis herbal extract in 
45% EtOH 
12.8  12.5 13 
Hydrastis canadensis mother tincture in 
69% EtOH 
8.2 8 8.5 
Solvent: 45% EtOH 6 6 6 
Solvent: 69% EtOH 6 6 6 
Controls 
Streptomycin HLS 300 mcg 27.6 27 28 
Trimethoprim TR 5 mcg 6 6 6 
Empty disc  6 6 6 
Distilled water  6 6 6 
Escherichia coli 
Hydrastis canadensis herbal extract in 
45% EtOH 
6 6 6 
Hydrastis canadensis mother tincture in 
69% EtOH 
6 6 6 
Solvent: 45% EtOH 6 6 6 
Solvent: 69% EtOH 6 6 6 
Controls 
Trimethoprim TR 5 mcg 24 24 24 
Penicillin-G P10 (10 units; 5.6 mcg) 6 6 6 
Empty disc  6 6 6 
Distilled water  6 6 6 
Table 4.1 Summary of the Kirby-Bauer Disk Diffusion Susceptibility 
Test against S. aureus and E. coli reference strains. The 
data is given in millimeters and the disk diameter is 6mm 
which indicates no growth inhibition on the plates.   
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4.3 Microdilution method 
The compounds were tested by serial dilution method in 96 well plates and 
labeled accordingly. Into each well 100 µl Mueller-Hinton broth was added 
and plates were divided into two and six wells per row used for the 
dilutions. This method was used to confirm the results obtained with Kirby-
Bauer Disk Diffusion Susceptibility method and to determine the Minimum 
Inhibitory Concentration (MIC) in the cases where there was bacterial 
growth inhibition. The tests were conducted on both S aureus and E. coli 
reference strains. Figure 4.3 below shows S. aureus and the typical 96 
well plate layout used to test the compounds using the Microdilution 
method. All wells contained S. aureus except for the media control (blank 
well). The wells that resemble a purple colour after the addition of the 
Iodonitrotetrazolium chloride (INT) dye showed bacterial growth thus 
indicating no inhibition of bacterial growth (still alive and able to grow) by 
the compounds. The wells that remained unchanged in colour after the 
addition of the test compound and INT dye indicates no bacterial growth 
therefore showing bacterial inhibition by the compounds. The dilutions (x) 
displayed at each well indicates the dilution from the first well to the sixth 
well and the decrease in concentration by 50 µl explained in chapter three. 
4.3.1 S. aureus  
The results gathered from the Microdilution method to determine the MIC 
confirmed that both Hydrastis canadensis herbal extract and Hydrastis 
canadensis mother tincture had positive antibacterial effects against S. 
aureus. The highlighted wells indicate the last concentration at which there 
was total inhibition of growth. The data showed that Hydrastis canadensis 
herbal extract had a greater inhibitory effect as compared to the Hydrastis 
canadensis mother tincture. The herbal extracts inhibition went up to the 
16x dilution as there was no colour change after the addition of the INT 
dye and from the 32x dilution a colour change from yellow to purple can be 
seen indicating bacterial growth. The Hydrastis canadensis mother tincture 
only went up to the 8x dilution as there was no colour change but from the 
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16x dilution there is a colour change from yellow to purple observed 
indicating bacterial growth. The 69% EtOH had a minor inhibitory effect as 
there was very little colour change observed until the 4x dilution. The 
blank, bacterial only and Trimethoprim TR 5 mcg (antibiotic negative 
control) wells showed no effects against S. aureus and Streptomycin HLS 
300 mcg (antibiotic positive control) showed the highest inhibition of 
growth with dilutions exceeding the 64x dilution as there was no visible 
colour change to purple  as suspected. 
Figure 4.3 A 96 well plate used to determine the MIC of the Hydrastis 
canadensis herbal extract and Hydrastis canadensis mother 
tincture against S. aureus. The plate was divided in half to 
allow for six serial dilutions as indicated above the wells of 
the first row. 
The results obtained from the MIC experiments are shown in table 4.2. It 
must be noted that the results shown for the herbal extract was not 
corrected for the inhibitory effect of the solvent. The dilution (x) indicates 
the last concentration at which total bacterial inhibition was observed 
i.e.no colour change (remains yellow).  
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Table 4.2 Showing a summary of the MIC of Hydrastis canadensis 
herbal extract and Hydrastis canadensis mother tincture 
against S. aureus. The data is given as dilution factor that 
inhibited bacterial growth. 
 
Test Dilution factor in 
triplicate 
Hydrastis canadensis herbal extract in 
45% EtOH 
16x / 16x / 16x 
Hydrastis canadensis mother tincture 
in 69% EtOH 
8x / 8x / 8x 
Solvent – 45% EtOH <2x / <2x / <2x 
Solvent – 69% EtOH <2x / 4x / 4x 
Streptomycin HLS 300 mcg >64x / >64x / >64x  
Trimethoprim TR 5 mcg <2x / <2x / <2x 
Media (blank disc) <2x / <2x / <2x 
Bacteria (S. aureus only) <2x / <2x / <2x 
. <Less than  
>Greater than 
4.3.2 E. coli   
The results obtained from the MIC experiments for the E. coli was difficult 
to interpret due to the yellow colour of the Hydrastis canadensis as seen in 
figure 4.4. 
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Figure 4.4  A 96 well plate used to determine the MIC of the Hydrastis 
canadensis herbal extract and Hydrastis canadensis mother 
tincture against E. coli showing the difficulty with data 
interpretation. The plate was divided in half to allow for six 
serial dilutions as indicated above the wells of the first row.  
It was then decided to repeat the experiments in 24 well plates to 
determine if E. coli growth was inhibited (figure 4.5 below). The results 
showed that using this method both Hydrastis canadensis herbal extract 
and Hydrastis canadensis mother tincture had positive antibacterial effects 
against E. coli as the INT dye was not metabolized although the herbal 
extract had a more prominent effect as compared to the mother tincture. 
This could possibly be linked to the fact that more than double the volume 
of the extract was added for this method, compared to the Kirby-Bauer 
Disk diffusion Susceptibility test. Thus, Hydrastis canadensis herbal 
extract and mother tincture could potentially inhibit E. coli when taken 
concentrated or in repeated doses. 
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Figure 4.5 A 24 well plate used to determine the MIC of the Hydrastis 
canadensis herbal extract and Hydrastis canadensis mother 
tincture against E. coli. The plate was divided in half to allow 
for three serial dilutions as indicated above the wells of the 
first row. 
Since the MIC results differed from the Kirby-Bauer Disk Diffusion 
Susceptibility Test results, it was decided to do a follow up experiment to 
determine if the E. coli growth was inhibited (bacteriostatic action) or if the 
cells were killed (bactericidal action) by the compounds. Samples from the 
wells from the 24 well plates grown overnight were plated onto Mueller-
Hinton agar plates to determine if the cells grew when removed from the 
compound. Figure 4.6 below shows Mueller-Hinton agar plates that were 
streaked with cells from the wells in figure 4.5 above to confirm the 
presence of viable cells after treatment of the E. coli cells. The Hydrastis 
canadensis herbal extract showed no viable cells after streaking up to the 
8x dilution (bactericidal) and the Hydrastis canadensis mother tincture 
showed no viable cells at the 2x dilution but thereafter it was found that the 
bacteria was still alive (bacteriostatic).   
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Figure 4.6 Mueller-Hinton agar plates that were streaked with cells from 
the wells in Figure 4.5 to confirm the presence of viable cells 
after treatment of the E. coli cells with both the Hydrastis 
canadensis herbal extract and Hydrastis canadensis mother 
tincture. 
The first observation at this stage is that more dilutions need to be done to 
determine the bacteriostatic concentration (BSC) and bactericidal 
concentration (BCC) of the Hydrastis canadensis herbal extract. Secondly, 
the BSC and BCC concentrations of the Hydrastis canadensis mother 
tincture against E. coli differed from the Hydrastis canadensis herbal 
extract, killing the cells up to two times diluted as compared to the 
Hydrastis canadensis herbal extract that killed the cells up to eight times 
its dilution. After a further two times dilution the Hydrastis canadensis 
mother tincture only inhibited the bacterial growth (4 x dilution) but did not 
kill the bacterial cells. The results obtained (as shown in figure 4.5 and 
figure 4.6) are summarized in table 4.3 to assist the reader with 
interpreting the data when comparing the bacteriostatic (figure 4.5) and 
bactericidal (figure 4.6) concentrations of the Hydrastis canadensis herbal 
extract and Hydrastis canadensis mother tincture against E. coli.  
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Table 4.3 A summary of the bacteriostatic and bactericidal effects of 
the Hydrastis canadensis herbal extract and Hydrastis 
canadensis mother tincture against E. coli. The data is 
shown as the presence or absence of growth at the given 
concentration. 
 Dilution 
Test 2x 4x 8x 
Hydrastis canadensis herbal extract    
Bacteriostatic concentration1 - - - 
Bactericidal concentration2 - - - 
Hydrastis canadensis Mother Tinctures    
Bacteriostatic concentration1 - - + 
Bactericidal concentration2 - + + 
1The dilution was determined from the results in figure 4.5 
2The dilution was determined from the results in figure 4.6 
-Bacterial death  
+Bacterial growth 
 
This, along with the rest of the results, will be discussed in more detail in 
the next chapter.   
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CHAPTER FIVE  
5. DISCUSSION OF RESULTS 
5.1. Discussion of experimental results of S. aureus 
5.1.1. Kirby-Bauer Disk Diffusion method 
The antimicrobial effects of Hydrastis canadensis herbal extract and 
Hydrastis canadensis mother tincture were evaluated by the degree at 
which the compounds inhibited the bacterial growth of S. aureus. The 
disks used had diameters of 6 mm and all measurements shown as 6 mm 
demonstrates no inhibition of bacterial growth. Experiments were 
conducted in triplicate and each disk measured twice for accuracy and 
reliability of the results. The average for each measurement was 
calculated and used as the zone of inhibition for every disk.  
Table 4.1 shows the average measurements of all the plates. The 
Hydrastis canadensis herbal extract had an average measurement of 12.8 
mm, this could be due to the active ingredient berberine which is the major 
alkaloid that contributes towards the antimicrobial activity of Hydrastis 
canadensis (Patil et al., 2015; Verma and Sharma, 2018; Wallace et al., 
2018) in comparison to the Hydrastis canadensis mother tincture which 
had an average of 8.2 mm confirmed by the study conducted by Rehman 
et al. (2018) where Hydrastis canadensis mother tincture showed 
antimicrobial effects against S. aureus by Disk Diffusion methods with an 
average zone of inhibition of 16 mm.  
The 45% EtOH used to prepare the Hydrastis canadensis herbal extract 
and the 69% EtOH used to prepare the Hydrastis canadensis mother 
tincture showed no effects against the bacterial growth of S. aureus as 
there were no visible zones of inhibition (6 mm), however according to 
Peters et al. (2012) a study was conducted on the antimicrobial effects of 
ethanol on S. aureus and found that from 50% EtOH was required to 
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inhibit the regrowth of S. aureus but this could be due to the dosage and 
duration of the treatment of EtOH as compared to this study. The empty 
disc, Trimethoprim TR 5 mcg (antibiotic negative control) and the distilled 
water showed no bacterial inhibition as expected.  
The Streptomycin HLS 300 mcg (antibiotic positive control) produced the 
largest zone of inhibition on both plates, measuring an average of 27.6 
mm which according to Zajmi et al. (2015) a study was conducted with the 
use of Streptomycin against S. aureus by Disk Diffusion and Dilution 
methods, results revealed that Streptomycin with a zone of 25.33 mm had 
bactericidal activity against S. aureus as expected. There are limited 
studies on the antimicrobial activity of Streptomycin against S. aureus due 
to the increasing bacterial resistance to the antibiotic (Saba et al., 2017; 
Moreno-Grúa et al., 2018). A study conducted on 156 samples of meat 
obtained in morocco found 63 samples of S. aureus isolates and tested it 
against 16 antibiotics and found that 84.13% of the S. aureus isolates 
were resistant to Streptomycin amongst many other antibiotics (Ed-dra et 
al., 2018).  
As seen in table 4.1 Hydrastis canadensis herbal extract and Hydrastis 
canadensis mother tincture both showed significant antibacterial effects 
against S. aureus, however the Hydrastis canadensis herbal extract had 
the most prominent inhibitory effect as compared to the Hydrastis 
canadensis mother tincture. The antibacterial effects were proven by the 
following studies. A study was conducted using Hydrastis canadensis 
extract in liquid extracts, powders and solids against Multidrug-resistant S. 
aureus (MDRSA) and beneficial gut bacteria Lactobacillus acidophilus (L. 
acidophilus) by Dilution methods to determine the MIC. Results revealed 
that Hydrastis canadensis liquid extract had greater activity against 
MDRSA and minimum activity against L. acidophilus (Rangineni, 2011). 
According to Cech et al. (2012) a study was conducted to show the 
antimicrobial activity of Hydrastis canadensis extract against Methicillin-
resistant S. aureus (MRSA) by the Broth Dilution method to determine the 
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MIC. The extract from the leaves showed more potent activity than the 
alkaloid berberine (75 µg/mL and 150 µg/mL, respectively) however, the 
concentration and method of preparation differed in comparison to this 
study as the root and rhizome of the plant was used to prepare the 
Hydrastis canadensis herbal extract and the dried roots for the Hydrastis 
canadensis mother tincture. Despite the difference in plant portions used, 
Hydrastis canadensis still possess the ability to inhibit bacterial growth of 
S. aureus. There is limited literature to support the antimicrobial effects of 
Hydrastis canadensis mother tincture. 
5.1.2. Microdilution method  
The Microdilution method was used to confirm the results obtained from 
the Kirby-Bauer Disk Diffusion Susceptibility method and to determine the 
MIC. Table 4.2 shows a summary of MIC of Hydrastis canadensis herbal 
extract and Hydrastis canadensis mother tincture against S. aureus. The 
dilution factors (x) indicate the last dilution at which there is still total 
bacterial inhibition before there is the colour change to purple, indicating 
bacterial growth (bacteria still alive). 
Hydrastis canadensis herbal extract showed bacterial inhibition up until the 
16x dilution as there was no colour change after the addition of the INT 
dye and from the 32x dilution there is a colour change from yellow to 
purple indicating bacterial growth as seen in figure 4.3. According to 
Scazzocchio et al. (2001) the antibacterial activity of Hydrastis canadensis 
extract and its major alkaloids: β-hydrastine, berberine, canadine and 
canadaline were tested against S. aureus by Microdilution methods to 
determine the MIC and found that all alkaloids had bacteriostatic effects 
against Gram-positive bacteria except for β-hydrastine where it showed no 
inhibition, thus confirming the results. Another study was conducted on the 
antimicrobial effects of berberine, hydrastine and canadine isolated from 
Hydrastis canadensis against MRSA by Microdilution methods to 
determine the MIC. The results showed that hydrastine and canadine were 
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inactive against MRSA but with the addition of berberine, antimicrobial 
effects were seen against MRSA amongst all actives (Pervaiz et al., 2016). 
The alkaloids and active components could not be calculated for the 
Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture used in this study but all above mentioned alkaloids still form part 
of the plant and is relevant to the study.   
Hydrastis canadensis mother tincture showed bacterial inhibition up until 
the 8x dilution as there was no colour change after the addition of the INT 
dye and from the 16x dilution there is a colour change from yellow to 
purple indicating bacterial growth as seen in figure 4.3, thus it can 
therefore be observed that the higher the concentration of both the 
Hydrastis canadensis herbal extract and the Hydrastis canadensis mother 
tincture or the increase in frequency of doses has the potential to inhibit 
the growth of S. aureus (Bell and Koithan, 2012; Bell and Schwartz, 2013; 
Dei, 2017).  
The 45% EtOH showed no effects against S. aureus however the 69% 
EtOH showed a minor inhibitory effect up until the 4x dilution. This is due 
to the ability of EtOH to kill off certain types of bacterial and can be used 
as a form of sterilization to disinfect equipment and surfaces thus 
confirming the results based on the study conducted by Peters et al. 
(2013) on the antimicrobial effects of EtOH on S. aureus and found that 
inhibition of the regrowth of S. aureus can be seen from 50% EtOH. A 
study conducted by Valle et al. (2016) tested up to 99% EtOH and 
methanol extracts against seven various MRSA strains by Disk Diffusion 
and Microdilution methods. EtOH had a more prominent antimicrobial 
effect with zones of inhibition ranging from 28-38 mm as compared to 
methanol with zones of inhibition ranging from 24-34 mm. The MIC for 
both extracts ranged between 19-625 µg/mL, confirming that EtOH had 
the potential to inhibit bacterial growth. 
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The Trimethoprim TR 5 mcg (antibiotic negative control) showed no 
bacterial inhibition due to the visible colour change to purple confirming 
bacterial growth present. According to Estrada et al. (2016), Trimethoprim 
is effective against Gram-negative bacteria as opposed to S. aureus which 
is a Gram-positive bacterium which therefore confirms the results but it 
could also be due to resistance that developed to S. aureus during the 
1980’s. The Streptomycin HLS 300 mcg (antibiotic positive control) 
showed significant bacterial inhibition across all dilutions as there was no 
visible colour change indicating no bacterial growth. A study conducted by 
Ahmed et al. (2013) tested the antimicrobial effects of Streptomycin (10 
µg) against S. aureus by Kirby-Bauer Disk Diffusion and Microdilution 
methods to determine the MIC. The 58 S. aureus isolates obtained from 
diseased human tissues were tested and Streptomycin showed 
antimicrobial activity against 32%-36% of the isolates and the remaining 
62% of the isolates showed resistance to Streptomycin, which confirms 
the results but also indicates that each strain of S. aureus is different, 
develops resistance in various ways and reacts differently to antibiotics 
and other compounds. 
The results obtained from the Microdilution method to determine the MIC 
as seen in table 4.2 confirmed that both Hydrastis canadensis herbal 
extract and Hydrastis canadensis mother tincture had positive antibacterial 
effects against S. aureus with Hydrastis canadensis herbal extract having 
a more prominent effect. As proven by Knight (1999), a study was 
conducted on the antimicrobial effects of Hydrastis canadensis herbal 
extract and penicillin against S. aureus, P. aeruginosa and P. pyogenes by 
Microdilution methods in order to determine the MIC. Hydrastis canadensis 
showed inhibitory effects in larger concentrations (Bandyopadhyay et al., 
2018) (300-4000 µg/mL) as compared to penicillin that showed inhibitory 
effects at a smaller concentration (0.98 µg/mL) against S. aureus thus 
confirming the results and indicating that the antimicrobial effects could be 
dependent on frequent doses and increasing the concentration to get the 
desired effects (Bell and Koithan, 2012; Bell and Schwartz, 2013; Dei, 
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2017). A mass spectrometry assay was conducted by Leyte-Lugo et al. 
(2017) on 8 compounds found in Hydrastis canadensis leaves to 
determine the bacterial efflux pump (factor that contributes to bacterial 
having the ability to become resistant) inhibitory activity against S. aureus. 
The results proved the efficacy of Hydrastis canadensis extract as a form 
of treatment against bacterial infections. According to Junio et al. (2011) 
the 3 flavonoids, sideroxylin, 6-desmethyl sideroxylin and 8-desmethyl 
sideroxylin found in Hydrastis canadensis were shown to synergistically 
enhance the antimicrobial effects of berberine (Hydrastis canadensis 
alkaloid) against S. aureus by facilitating the accumulation of berberine 
within the cells of bacteria and therefore inhibiting its multidrug resistance 
pump. The flavonoids were found in higher concentrations in the leaves 
and the alkaloid berberine had higher concentrations in the roots of the 
plant.  In order to get optimal effects a combination of both leaves and 
roots of Hydrastis canadensis can be beneficial to the efficacy of the plant 
against various bacteria (Junio et al., 2011). 
5.2 Discussion of experimental results of E. coli 
5.2.1 Kirby-Bauer Disk Diffusion method 
The Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture both had no inhibitory effect on E. coli, as both plates showed no 
measurable zones of inhibition (6 mm) however, a study conducted by 
Bandyopadhyay et al. (2013) investigated the antibacterial effects of 
Hydrastis canadensis active ingredient berberine against 10 entero-
virulent E. coli strains obtained from haemorrhagic diarrhoea samples by 
Disk Diffusion and Broth Dilution methods. Berberine showed antibacterial 
activity in a dose dependant manner which does not confirm the results as 
repeated doses were not applied to this study, perhaps if repeated or 
concentrated doses were applied, an antibacterial effect could have been 
seen (Bandyopadhyay et al., 2013). A study on the antimicrobial effects of 
Hydrastis canadensis mother tincture and ciprofloxacin (10 µl) against E. 
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coli by Agar Disk Diffusion method showed that Hydrastis canadensis 
mother tincture has positive antimicrobial effects against E. coli due to a 
zone of inhibition of 14 mm (Rehman et al., 2018). There is limited 
literature available on the effects of Hydrastis canadensis against E. coli.  
The 45% EtOH used to prepare the Hydrastis canadensis herbal extract 
had no effect on E. coli however the 69% EtOH used to prepare the 
Hydrastis canadensis mother tincture had a minor inhibitory effect on E. 
coli that was not measurable in mm but could be observed on the plate 
(figure 4.2 B). The minor inhibitory effect could be due to the antimicrobial 
properties of EtOH to kill off certain types of bacterial and can be used as 
a form of sterilization to disinfect equipment and surfaces (Lorian, 2015) 
confirmed by Thaddeus et al. (2018) indicating that from 60% EtOH minor 
inhibitory effects against E. coli and Candida albicans were observed and 
had optimal effects at 85-95% EtOH.   
The Streptomycin HLS 300 mcg (antibiotic positive control) displayed 
inhibition in all tests. The study conducted by Hu et al. (2017) tested 
Streptomycin against carbapenem-resistant Enterobacteriaceae which 
included 5 E. coli isolates by Broth Dilution methods to determine the MIC 
showed positive antibacterial activity against all strains, confirming the 
results.  
The Trimethoprim TR 5 mcg (antibiotic positive control) inhibited the 
growth of E. coli with significantly visible zones of inhibition measuring at 
24 mm as proven by Aghraz et al. (2018) where Trimethoprim was tested 
against E. coli and yielded positive antimicrobial results as expected. Due 
to both antibiotics displaying positive results it was therefore decided to 
include Penicillin-G P10 5.6 mcg as an alternative antibiotic negative 
control to ensure that the experiments worked. Penicillin-G P10 5.6 mcg 
showed no inhibition against E. coli with a zone of inhibition of 6 mm. 
There is limited literature on the antimicrobial effects of Penicillin against 
E. coli due to the rapid development of resistance to the antimicrobial 
 
 
59 
 
agent. A study conducted by Odonkor and Addo, (2018) tested 14 different 
antibiotics against E. coli isolates obtained from six various water sources 
by the Kirby-Bauer Disk diffusion Susceptibility method. The results 
showed that E. coli possessed high resistance patterns and amongst all 
antibiotics, E. coli was most resistant to penicillin with almost 50% of the 
isolates resistant to it.  
The empty disc and distilled water showed no inhibitory effects as water is 
a pure substance free compound comprised of two hydrogen molecules 
and one oxygen molecule (Misner, 2011; Kasaai, 2014).  
5.2.2. Microdilution method 
At this point it was suspected that both the Hydrastis canadensis herbal 
extract and Hydrastis canadensis mother tincture only had effects on 
Gram-positive bacteria such as S. aureus and not Gram-negative bacteria 
such as E. coli. The Microdilution method was conducted to confirm the 
results obtained from the Kirby-Bauer Disk Diffusion Susceptibility method. 
The MIC was conducted using 96 well plates for both compounds but due 
to poor visibility and difficulty in interpreting the data as seen in figure 4.4, 
the experiment was therefore repeated in a 24 well plate where the 
compound was forced into contact with E. coli as seen in figure 4.5. It was 
discovered that the results differed in comparison to the Kirby-Bauer Disk 
Diffusion method, Hydrastis canadensis herbal extract and Hydrastis 
canadensis mother tincture both showed positive antibacterial effects 
against E. coli, the Hydrastis canadensis herbal extract more prominent 
than the Hydrastis canadensis mother tincture.  
The Hydrastis canadensis herbal extract showed inhibition till the 8x 
dilution as no visible colour change from yellow to purple was seen, 
proven by the study conducted by Scazzocchio et al. (2001) where the 
antimicrobial activities of Hydrastis canadensis extract and its alkaloids: 
berberine, canadine, canadaline and β-hydrastine were tested against E. 
coli by measuring the killing time and bacteriostatic activity by MIC in liquid 
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medium. The killing time observed was from 4-30 minutes. The extract and 
all its alkaloids had antimicrobial effects against E. coli except for β-
hydrastine and canadine where it showed no inhibition. Another study 
conducted by Boberek et al. (2010) exposed berberine to E. coli by the 
use of Microdilution methods to determine the MIC and Fluorescence 
Microscopy testing. Results showed that berberine formed filaments, 
indicating an antimicrobial mechanism that includes cell division inhibition. 
It was found that berberine targets and inhibits bacterial division proteins 
which stop bacteria from multiplying thus contributing to its antimicrobial 
effects.  
The Hydrastis canadensis mother tincture only showed inhibition till the 2x 
dilution as no visible colour change was seen from yellow to purple. The 
purple colour change can be seen from the 4x dilution indicating bacterial 
growth. There is limited literature to support the antimicrobial effect seen in 
Hydrastis canadensis mother tincture. The 24 well plate method used 
double the volume of both compounds than any of the above mentioned 
methods. It can therefore be gathered that with a greater concentration of 
both compounds especially the Hydrastis canadensis mother tincture and 
at repeated doses they could potentially inhibit E. coli (Bell and Koithan, 
2012; Bell and Schwartz, 2013; Dei, 2017). 
When E. coli comes into contact with the compound it demonstrated the 
ability to move away from the test compound producing a “halo” effect as 
seen in figure 5.1. The Halo (moon) increases across each well therefore 
as the concentration of the compound decreases as will the halo. E. coli 
has the ability to partake in bacterial swarming, where the bacterium 
moves away due to its flagella-driven motility over a surface in order to 
save itself (Swiecicki et al., 2013). When the compound was forced into 
mixture with E. coli by method of shaking them together, the bacteria was 
unable to move away fast enough to separate them from the compound 
resulting in better antimicrobial results and counteracting the possible 
swarming or swimming effect.  
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Figure 5.1 Demonstration of the “halo” effect produced by E. coli in 
response to contact with the test compound. 
According to Zhang et al. (2010) this effect is dependent on the 
composition of the agar that allows E. coli to either swim or swarm. E. coli 
can experience either swimming (move within water filled channels inside 
agar) or swarming (move across solid or semi-solid agar media). At lower 
concentrations of the antimicrobial agent the bacteria is able to protect 
itself by creating a barrier to absorb the effect of the compound, moving 
away as well as sacrificing cells at the surface in order to be preserve 
nutrients as well be perceived as dead (Swiecicki et al., 2013; Ford et al., 
2018; Little et al., 2018) which may have been the reason why the Kirby-
Bauer Disk Diffusion and the initial Microdilution method yielded negative 
results. When the experiment was done on the 24 well plate the 
concentration of the compounds was increased, and the possible 
swimming effect reduced, therefore further suggesting that that Hydrastis 
canadensis works in a dose dependent manner (Bell and Koithan, 2012; 
Bell and Schwartz, 2013; Bandyopadhyay et al., 2013; Dei, 2017).  
A further experiment was conducted due to the two different results 
obtained from previous experiments to determine if the E. coli growth was 
inhibited or if the cells were killed by the compounds. Samples from the 
wells were plated onto Mueller-Hinton agar as seen in figure 4.6 and it 
was found that according to the 2x, 4x and 8x dilution of the Hydrastis 
canadensis herbal extract there were no viable cells able to grow on the 
plates making it bactericidal. The Hydrastis canadensis mother tincture 
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were also plated and it showed that the 2x dilution had no viable cells but 
when samples from 4x and 8x dilutions were grown, there were viable 
cells indicating there was bacterial inhibition but cells were still alive 
making it bacteriostatic. Results obtained show that the effects of the 
Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture is both bactericidal (kills cells) and bacteriostatic (stops bacteria 
from reproducing) and depends on the concentration of the compound 
added supporting the previous statement that there may be a dose 
response for the Hydrastis canadensis herbal extract and Hydrastis 
canadensis mother tincture. This was similar to results reported by 
previously mentioned studies (Scazzocchio et al., 2001; Rangineni, 2011); 
Cech et al., 2012; Bell and Koithan, 2012; Dei, 2017; Rehman et al., 
2018). 
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CHAPTER 6 
6. CONCLUSION & RECOMMENDATIONS  
6.1 Conclusion 
The results demonstrated that Hydrastis canadensis herbal extract and 
Hydrastis canadensis mother tincture inhibited the growth of S. aureus 
which was confirmed by the Kirby-Bauer Disk Diffusion and Microdilution 
methods. The Hydrastis canadensis herbal extract and Hydrastis 
canadensis mother tincture inhibited the growth of E. coli but was only 
confirmed by the adaptation of the 96 well microdilution methods. The 
Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture showed no antimicrobial effects when tested with the Kirby-Bauer 
Disk Diffusion method as bacterial swarming, minimum dosing or 
decreased concentration could have been a factor. Overall it was found 
that the herbal extract had a greater antimicrobial effect than the mother 
tincture. 
Further investigation into why the microdilution method yielded positive 
results rather than the Kirby-Bauer Disk Diffusion method for E. coli found 
that, E. coli’s flagella driven motility allowed the bacteria to swim away and 
protect itself from the compound resulting in a false negative. When E. coli 
was forced into contact with the compound, inhibition of growth was 
observed.  
Despite the lower concentration of active ingredients found in homeopathic 
mother tinctures due to the dilution factors as compared to the higher 
concentration of herbal extracts, an antimicrobial effect was observed by 
the homeopathic mother tincture. In order to obtain further positive results 
an increased concentration or successive doses could potentially kill 
bacteria growth, which is how homeopathic medicines are prescribed.  
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It was hypothesised that both the herbal extract and homeopathic mother 
tincture of Hydrastis canadensis would display antimicrobial effects 
against S. aureus and E. coli by inhibiting the growth of the organisms on 
solid and in liquid culture media which was supported and confirmed by 
this study. 
In conclusion, Hydrastis canadensis did work against S. aureus and to an 
extent against E. coli but we need a better understanding of whether it is 
bactericidal or bacteriostatic. It needs to be ensured that when using this, 
it is the correct method and that we test and expand the number of strains 
to determine if there is no interchange and how it relates to antibiotic 
resistance. This experiment has had a positive impact towards 
Homeopathy as well as contributed to the growing knowledge of the 
antimicrobial effects of Hydrastis canadensis and the evolution of bacteria 
over decades.  
6.2 Recommendations and Limitations  
Further research can be conducted based on this study to ensure the 
results of this study are conclusive. Below are some recommendations:  
• Determine which method works the best. 
• Retest with more bacterial strains preferably disease causing strains.  
• Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture could be tested on other types of bacteria such as Group B 
Streptococcus, Streptococcus pyogenes, Listeria monocytogenes, 
Campylobacter jejuni ect.  
• Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tincture could be tested on other types of bacteria at various ranges of 
concentrations to reveal the most effective concentration and 
susceptible bacterial strains. 
• Different types of herbal extracts could be tested on S. aureus and E. 
coli. 
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• Different types of homeopathic mother tinctures and other medicines 
could be tests on S. aureus and E. coli. 
• Various herbal extracts and homeopathic medicines could be tested on 
different types of bacteria. 
• The antimicrobial effects of other extracts and tinctures could be tested 
with the same testing methods.  
• The antimicrobial effects of Hydrastis canadensis herbal extract and 
Hydrastis canadensis mother tincture could be determined by the use 
of other testing methods.  
• Hydrastis canadensis Herbal extract dilutions could be taken further to 
determine at which concentration are there still viable cells with regards 
to S. aureus and E. coli, as the herbal extract displayed stronger 
antimicrobial effects. 
• Hydrastis canadensis mother tinctures concentrations could be 
increased or repeated to determine which concentration is most 
effective at destroying viable cells.  
• The flagella driven motility and adaptation of E. coli could be further 
investigated from this study. 
• Different forms of the plant Hydrastis canadensis can be used with this 
experiment such as leaves, capsules, powders ect.  
• Hydrastis canadensis herbal extract and Hydrastis canadensis mother 
tinctures active ingredients could be tested and calculated before 
conducting the experiments.  
Certain limitations were experienced during this study. Below are some of 
those limitations: 
• different plant samples for both compounds and the methods of 
preparation for each 
•  inability to calculate active ingredients  
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